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Abstract  47 
This review is in two sections. The first section summarises thirty-five conditions, both common and infrequent, 48 
causing cicatrising conjunctivitis. Guidelines for making a diagnosis are given together with the use of 49 
diagnostic tests, including direct and indirect immunofluorescence, and their interpretation. The second 50 
section evaluates our knowledge of ocular mucous membrane pemphigoid, which is the commonest cause of 51 
cicatrizing conjunctivitis in most developed countries. The clinical characteristics, demographics and clinical 52 
signs of the disease are described. This is followed by a review and re-evaluation of the pathogenesis of 53 
conjunctival inflammation in mucous membrane pemphigoid (MMP), resulting in a revised hypothesis of the 54 
autoimmune mechanisms causing inflammation in ocular MMP. The relationship between inflammation and 55 
scarring in MMP conjunctiva is described. Recent research, describing the role of aldehyde dehydrogenase 56 
(ALDH) and retinoic acid (RA) in both the initiation and perpetuation of profibrotic activity in MMP conjunctival 57 
fibroblasts is summarised and the potential for antifibrotic therapy, using ALDH inhibition, is discussed. The 58 
importance of the management of the ocular surface in MMP is briefly summarised.  This is followed with the 59 
rationale for the use of systemic immunomodulatory therapy, currently the standard of care for patients with 60 
active ocular MMP. The evidence for the use of these drugs is summarised and guidelines given for their use. 61 
Lastly the areas for research and innovation in the next decade are reviewed including the need for better 62 
diagnostics, markers of disease activity, and the potential for biological and topical therapies for both 63 
inflammation and scarring.  64 
 65 
Keywords  66 
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Introduction 72 
It is a great privilege to have been asked to give this lecture and I am very grateful to the Scientific Committee 73 
of the College for inviting me to undertake it. I am going to discuss the results of 25 years of studies both 74 
collaborating with, and supported by, a large number of colleagues, including scientists and clinicians. I will use 75 
our studies in the context of the available evidence base to describe the causes and diagnosis of cicatrising 76 
conjunctivitis (CC) and follow this with a review of mucous membrane pemphigoid (MMP), which is the most 77 
common cause in developed countries. I hope that what I have to say about a group of diseases that is 78 
challenging for both patients and clinicians, will interest, entertain and challenge you as much as it has me.  79 
 All previous Bowman Lecturers have felt that their predecessors have been hard acts to follow and I am no 80 
different. However, all of us have worked in the shadow of Sir William Bowman. The portrait in Figure 1 has 81 
rarely been seen. It was painted by George Watts in about 1865 when Bowman was at the height of his 82 
powers. Watts was a friend of Bowman’s and the leading portraitist of the day. Like many others who have 83 
given this lecture I became fascinated by Bowman’s life and achievements. I wanted to know what it was that 84 
made him one of the foremost scientists of his day for his work on histology, bringing him Fellowship of the 85 
Royal Society at the age of 25, and then going on to become one of the founders of Ophthalmology as a 86 
scientific discipline in the UK. I have drawn on the biographies by his  contemporary Power1, and by James2 for 87 
the background, but also on other sources to make some connections that have not, to my knowledge, been 88 
made before. These have been summarised in Supplementary Appendix 1.   89 
 In the early 19th century the classification of conjunctivitis was almost unrecognizable from what we know 90 
today. However, by the end of the 19th century trachoma, trauma, ocular rosacea, adenovirus, allergic eye 91 
disease, lupus and pemphigus (at that time a term including the all the pemphigoid diseases) had been 92 
recognized. A brief history of milestones in the recognition of the diseases causing CC is summarized in 93 
Supplementary Appendix 2 and Supplementary Table 1. 94 
 95 
Current causes, epidemiology and classification of cicatrising conjunctivitis  96 
Table 1 lists causes of CC from 2 studies. Thorne JE 20043 provides the largest institutional case series of CC 97 
cases attending an MMP clinic, either to have the cause of CC diagnosed, or to have ocular involvement by 98 
MMP excluded from those patients with an established diagnosis of extraocular MMP. But, causes in single 99 
clinics are skewed by case selection and referral bias. For this reason, the epidemiology of CC is best described 100 
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by the study from Radford C 20124 in the UK which lists the causes of cicatrizing conjunctivitis from the only 101 
national incidence study to have been reported. This study may have underestimated the incidence of CC by 102 
15%, but the figures for MMP are in line with those reported for that disease from French and German 103 
estimates of 1.13.per million in France and 0.87 per million in Germany4.  104 
 105 
Table 2 lists 30 causes of CC with references and notes about the associated diseases and the rarity of the 106 
conditions. Although not complete, it includes those reported causes for which there is reasonable evidence of 107 
causation. These diseases have been divided into three categories in Table 2, each of which relate to current 108 
treatment protocols.  109 
 110 
i Blinding scarring disorders include mucous membrane pemphigoid (MMP), and a rare subset of cases of 111 
drug induced scarring, and Stevens-Johnson syndrome/Toxic epidermal necrolysis (SJS/TEN), that behave 112 
like MMP and develop both inflammation and progressive scarring.  113 
 114 
ii Ocular surface neoplasia (OSN) is an uncommon cause of inflammation and scarring which may mimic 115 
MMP although it is usually, but not always, unilateral unlike MMP which is usually, but not always, 116 
bilateral. The oncology protocols required for treatment will be delayed by misdiagnosis as CC.   117 
 118 
iii Other conjunctival scarring diseases are those that have frequently been termed “pseudopemphigoid”.  119 
The reason for this distinction, and for the term pseudopemphigoid, has been summarized in the study 120 
from Thorne JE 2004 comparing MMP and with pseudopemphigoid3  where pseudopemphigoid is used as 121 
the term for non MMP causes of CC. “Other ocular surface diseases can cause cicatrizing conjunctivitis and 122 
symblepharon formation that mimic MMP. These diseases may be grouped under the term 123 
“pseudopemphigoid”. Although there are uncommon diseases associated with pseudopemphigoid that 124 
might require systemic immunosuppressive drug therapy (e.g., lichen planus or paraneoplastic pemphigus), 125 
most of the causes of pseudopemphigoid do not require systemic immunosuppressive drug therapy. 126 
Because long-term, systemic immune-suppressive drug therapy has potentially life-threatening side effects, 127 
differentiating ocular MMP from pseudopemphigoid is essential for the proper treatment of patients with 128 
cicatrizing conjunctivitis”.  129 
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 However, the use of “pseudopemphigoid” as a catch-all term for any cause of CC that shares the 130 
clinical features of MMP, but which demands a different therapeutic approach, is too non-specific to be 131 
helpful for several reasons. It groups diseases with very different aetiologies, some of which may be 132 
associated with severe inflammation, unresponsive to topical therapy, that require immunosuppressive 133 
treatment. These include severe atopic keratoconjunctivitis (AKC)5, graft versus host disease (GVHD)6, 134 
sarcoid7, ectrodactyly-ectodermal dysplasia-cleft syndrome EEC syndrome and ectodermal dysplasia (ED)8, 135 
even though the associated scarring rarely leads to pathology. Additionally , some of these conditions, with 136 
an established diagnosis, such as AKC and lupus, may also have concomitant MMP, which must be 137 
excluded. For these reasons the term pseudopemphigoid, as a specific term covering a disparate group of 138 
diseases, can be confusing and is best avoided.   139 
 140 
Making the diagnosis  141 
The diagnostic problem is shown by the similarity of the clinical appearances of the diseases illustrated in 142 
Figure 2. This has resulted in the difficulty we have in distinguishing many of the causes in Table 2 from ocular 143 
MMP and making a firm diagnosis, particularly for eye diseases without systemic associations or with dual 144 
pathology such as SJS/TEN, and for CC triggered by eye drops. Figure 3 summarises these dilemmas. Despite 145 
the similarities in the clinical characteristics some features of the clinical examination can help, as can a 146 
carefully taken history, and the appropriate investigations providing their limitations are understood.  147 
 148 
Clinical examination, given the similarity of the clinical phenotype, is principally useful for establishing whether 149 
the disease is unilateral, and therefore potentially caused by ocular surface neoplasia, and to identify signs 150 
associated with a few of the other causes. Ocular MMP is rarely unilateral with only 7/115 (6%) of cases in one 151 
of our series36.  Other clinical findings that contribute are: severe aqueous tear deficiency (rare in early ocular 152 
MMP) caused by both Sjögren’s syndrome and severe non-Sjögren’s dry eye, for which a low Schirmer’s 1 test 153 
(without anaesthesia) is indicative although not diagnostic because of limited sensitivity37. For ocular rosacea 154 
the scarring is associated with meibomitis and a papillary and follicular conjunctivitis with or without the 155 
following: pseudopterygium, peripheral corneal vascularisation and usually the dermatological features of acne 156 
rosacea38.  157 
 158 
 6
History: The other disorders listed in Table 2 have a clear history of an associated ocular condition or systemic 159 
disease with the exceptions listed below. Direct questions about the eye diseases, risks associated with 160 
scarring, and systemic diseases that are associated with CC (listed in Table 2) will identify whether the patient 161 
has an ocular or systemic disease in association with CC. This information will not always be volunteered by 162 
patients or referring physicians. The diseases which develop CC, without a history of an associated systemic 163 
disease, or which present in the eye before disease develop elsewhere are:  164 
• Ocular MMP (conjunctival disease without involvement of other sites) has comprised 32-48% of 132 165 
cases in two UK studies including both cases with and without identified autoantibodies but meeting 166 
clinical criteria4,39.  167 
• Paraneoplastic pemphigoid and pemphigus (PNP) may rarely present in the conjunctiva at the same 168 
time as a neoplasm, and before other signs of malignancy27.  169 
• Pemphigus vulgaris (PV) may present in the conjunctiva before other signs: one case series of this 170 
presentation has been described30. 171 
• Sarcoid may present in the conjunctiva and be associated with severe scarring7.   Conjunctival biopsy, 172 
even in the absence of conjunctival signs, can be diagnostic in 30% of patients with systemic 173 
sarcoidosis40.  174 
The rate of progression of scarring can usually be established by taking a careful history of the onset of 175 
symptoms of inflammation and scarring. The scarring may have been noticed by a healthcare professional or as 176 
a result of the onset of trichiasis. Estimating the rate of progression is important when deciding on the need for 177 
therapy, given the diagnostic delay for patients with ocular MMP (mean of 2.5 years and a range up to 10 178 
years)4. 179 
 180 
Patients with multiple causes of CC: as described in Table 2 patients with SJS/TEN and drug induced CC may 181 
rarely develop disease that is indistinguishable from ocular MMP. We also have one unreported case of MMP 182 
who later developed localised conjunctival OSSN. Other causes of CC including trachoma and atopic 183 
keratoconjunctivitis may also develop MMP and this can be expected to occur occasionally for any of the other 184 
causes. It follows that any patient with rapid progression of scarring and inflammation should have 185 
investigations to exclude MMP and OSSN.   186 
 187 
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When to investigate?  188 
Unilateral cases (to exclude OSN), patients without a clear history of an associated ocular or systemic disease 189 
presenting in the eye (such as occurs in ocular MMP, PNP, PV and Sarcoid), and those with an ocular or 190 
systemic disease, but with inflammation and scarring not responding to topical therapy. The latter is most 191 
common in SJS/TEN, and in topical drug associated CC, for whom there is often reluctance to discontinue 192 
topical therapy for advanced glaucoma. In the latter group severe inflammation and scarring may be associated 193 
with most non preserved glaucoma medications, as well as due to preservatives41: the inflammation will often 194 
rapidly resolve on withdrawal of the drops although this may take 2-6 weeks to improve and longer to 195 
resolve10. Oral acetazolamide will often be tolerated by this group of patients, at least for 1-2 weeks to confirm 196 
the diagnosis of toxicity/allergy to topical medications. If oral acetazolamide is not tolerated, topical 197 
unpreserved iopidine, to which few of these patients have been exposed, can be used as an alternative. We 198 
have had to carry out glaucoma tube surgery on some patients having these reactions.   199 
   200 
Which investigations to use?  201 
Our protocol for the investigation of CC cases is included in Supplementary Appendix 3. 202 
 203 
Blood tests are used in our department for the following: 204 
a. Indirect immunofluorescence and individual autoantibody detection to identify specific autoantibodies 205 
associated with MMP and PV.  206 
• Indirect immunofluorescence: Indirect immunofluorescence (IIF) microscopy on salt-split skin is used 207 
to identify the presence of serum autoantibodies in pemphigoid diseases. The structure of the 208 
basement membrane, its constituent proteins and the identification of these by immunofluorescence 209 
tests is illustrated in Figures 4 and 59. However, IIF is non-specific for individual antibodies which 210 
cannot be identified from this test. The technique is clearly described by Hintner42. 211 
• Autoantibody detection: autoantibodies to BP180, laminin 332 BP230, α6β4 integrin, laminin 311, 212 
type VII collagen, Laminin γ1 (p200 protein) are associated with MMP and those to the intraepithelial 213 
proteins desmoglein 1 and 3 are associated with pemphigus vulgaris43 which may occasionally present 214 
in the eye. ELISAs for antibodies to BP180, BP230, Collagen VII, Desmoglein 1 and Desmoglein 3 are 215 
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available from immunodermatology services and some laboratories offer immunoblotting to detect 216 
the remaining autoantibodies .  217 
  Although often negative in MMP, positive indirect immunofluorescence, or autoantibody 218 
detection, showing circulating anti-basement membrane zone antibodies provides additional evidence 219 
for an underlying autoimmune pathology44 and may occasionally be positive when DIF is negative3. 220 
b. Autoantibody screening, and inflammatory markers to identify patients at risk of subclinical autoimmune 221 
disease which is present in over 30% patients with MMP (compared to less than 10% in a control 222 
population)45. 223 
c. Baseline screening for patients who might need immunosuppressive therapy: full blood count, blood film, 224 
glucose 6 phosphate dehydrogenase (G6PD) level (dapsone is contraindicated if this is elevated, which is 225 
common in Mediterranean races), thiopurine methyltransferase (TPMT) levels relevant to metabolism of 226 
azathioprine, urea and electrolytes, creatinine, liver function tests, glucose and infection markers including 227 
quantiferon gold (for TB), hepatitis and HIV. 228 
 229 
Biopsies are taken for routine histopathology and direct immunofluorescence studies. Bulbar conjunctival 230 
biopsies are safe to take in patients with probable or proven MMP: of 344 cases having bulbar conjunctival 231 
biopsy no adverse effects were reported46-48. However, Foster reported that fornix conjunctival biopsies may 232 
be associated with an exacerbation of scarring in 3 cases, following which he abandoned this site for diagnostic 233 
biopsy46. The technique for taking biopsies has recently been described49. 234 
a. Routine histopathology with fixation in 10% formol saline is used to identify atopic keratoconjunctivitis50, 235 
sarcoid40 and is essential to exclude OSN, particularly in unilateral CC.  236 
b. Direct immunofluorescence (DIF) from perilesional tissue is required to confirm the diagnosis in the 237 
immunobullous diseases42,51. Figure 5 illustrates the differences between the DIF findings for the 238 
intraepithelial “pemphigus” diseases and the subepithelial “pemphigoid” diseases, first defined by Lever in 239 
195352. Lichen planus, an inflammatory disease affecting skin and sometimes the oral and ocular mucosa, 240 
is also shown. DIF is used to differentiate these conditions and is described in Figure 5.  241 
 242 
Interpretation of DIF results 243 
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Causes of cicatrising conjunctivitis which may be DIF positive from the conjunctiva and skin, or other mucosal 244 
sites, include:  245 
• MMP (including mucosal dominated EB. Linear IgA disease and anti-laminin 332 pemphigoid), some 246 
patients with SJS/TEN, some with drug induced scarring, all of which show IgG or IgA and complement on 247 
DIF at the epithelial basement membrane (shown in Figures 4 and 5), should be treated as MMP cases. 248 
Note that for the diagnosis of ocular MMP a conjunctival biopsy is NOT required for the diagnosis if there 249 
has been a positive biopsy from any other site (skin, buccal, genital, nasopharyngeal mucosa), providing 250 
the ocular findings are typical of MMP44. The DIF findings in BP are the same as for MMP so that the 251 
diseases must be differentiated on clinical grounds. 252 
• Pemphigus vulgaris may rarely present in the conjunctiva as conjunctivitis in addition to conjunctival 253 
scarring, and conjunctival DIF has shown the characteristic epithelial intercellular fluorescence to IgG and 254 
complement30 shown in Figure 5, that is typically found in the skin at the dermoepidermal junction 255 
(basement membrane zone) in PV42.  256 
• Lichen planus has a characteristic “ragged” fibrin basement membrane deposition as shown in Figure 544.  257 
 258 
Other diseases associated with CC, and which may have positive conjunctival DIF are:  259 
• The ectodermal dysplasias with a pattern identical to that of MMP in the conjunctiva8. 260 
• Lupus shows granular deposition of IgG, IgA, IgM and complement at the dermal basement membrane in 261 
many cases42 and also in the conjunctiva in CC cases associated with lupus53 . 262 
 263 
Conjunctival scarring associated disease which may be DIF positive from skin, but not from the conjunctiva:  264 
• Conjunctival DIF has not been demonstrated in paraneoplastic pemphigus, which may also be associated 265 
with conjunctival scarring, and show a similar pattern to that of PV, in addition to a pemphigoid like 266 
pattern at the dermal epidermal junction. 267 
• Dermatitis herpetiformis having a typical granular pattern at the basement membrane zone42. 268 
• Porphyria cutanea tarda also shows characteristic immunoglobulin deposition at the dermoepidermal 269 
junction but one study of associated conjunctival scarring showed repeatedly negative DIF results35.    270 
 271 
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Negative immunofluorescence findings in ocular MMP 272 
There is a strong recommendation, from an influential consensus document44, that MMP can only be 273 
diagnosed when both clinical criteria and direct immunopathology criteria have been fulfilled. The clinical 274 
criteria are those distinguishing MMP from other diseases involving mucous membranes. Those that are listed 275 
in the document, and which cause CC, are lichen planus, SJS/TEN, PV, PNP, BP, and drug induced CC, to which 276 
the additional disorders summarized in Table 2 must be added. The direct immunopathology criteria that are 277 
recommended, as mandatory for diagnosis, are either direct immunofluorescence (DIF) microscopy, which is 278 
widely available, or immunohistochemistry which is not. Both positive IIF or specific autoantibody detection are 279 
widely accepted as alternative evidence when DIF findings are negative.  280 
 These criteria are usually positive in MMP that involves tissues other than the eye. However negative 281 
DIF results have long been recognized as presenting a diagnostic problem in patients with strong clinical 282 
evidence of ocular only MMP (in whom the conjunctiva is the only site of involvement). In three studies 283 
describing this group of 49 patients3,47,54 25/49 (51%) were DIF+ of whom 13 (26%) required more than one 284 
biopsy to demonstrate this (Supplementary Table 2). Other problems with the use of DIF as a mandatory 285 
finding for the diagnosis of MMP are that the results can be initially positive, then subsequently negative when 286 
patients are in remission47. Identical biopsy findings are found in bullous pemphigoid, which has to be 287 
distinguished by the clinical findings, and identical findings are also reported in patients some patients with 288 
SJS/TEN11, drug induced progressive scarring55, ectodermal dysplasia8 and ulcerative colitis54. 289 
 Immunopathology, as described in the Consensus document, refers to the autoantibody detection 290 
tests (DIF, IIF or other means of autoantibody detection) that are recommended for diagnosis in these 291 
immunobullous disorders. However, the presence of autoantibodies does not reflect the dominance of the cell 292 
mediated autoreactive response, to mucosal basement membrane epitopes, which is probably important in 293 
many cases of ocular MMP (see sections b. and c. in the review of the pathogenesis of ocular MMP below). In 294 
effect a positive DIF result, as recommended for diagnosis, is a biomarker for an autoantibody driven 295 
autoimmune pathology and not the cellular autoimmune response. Unfortunately, DIF has not proved to be 296 
either sensitive in ocular MMP, nor specific as a marker for ocular MMP. Although a positive DIF result is useful, 297 
and can distinguish MMP from lichen planus, lupus erythematosus and PV and PNP, which have characteristic 298 
immune-pathological features of their own, a negative result does not exclude ocular MMP. Currently patients 299 
are being seen at Moorfields who could benefit from treatment for MMP, but who have been untreated 300 
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because of uncertainty about the diagnosis due to their having negative autoantibody results. This has resulted 301 
in delayed therapy and deterioration of their scarring and inflammation. For these reasons we have proposed 302 
new criteria for the diagnosis of ocular MMP that are summarised below.  303 
 304 
Recommended diagnostic criteria for ocular MMP.  305 
We have proposed 3 sets of criteria for the diagnosis of ocular MMP4,56,57: 306 
a. Patients with positive conjunctival DIF or positive DIF from another site meet currently agreed criteria44.  307 
b. Patients with negative DIF from any site and positive indirect immunofluorescence can be diagnosed as 308 
having MMP.  309 
c. Patients with negative immunopathology can be diagnosed with ocMMP providing that they have a typical 310 
phenotype of progressive conjunctival scarring, and that other diseases that may cause this phenotype 311 
have been excluded. When ocular cases are reported, the detailed immunopathology findings should be 312 
recorded so that the diagnosis can be interpreted in light of future modifications to diagnostic criteria. 313 
 314 
When to refer? 315 
Patients with scarring & inflammation if there are no facilities for the specialist investigations or for delivering 316 
immunomodulatory therapies, for rarely described diseases, when the diagnosis is uncertain and when there is 317 
a poor response to therapy. In these circumstances a specialist centre with expertise in CC can provide the 318 
resources both to clarify the diagnosis and establish a treatment plan4. Guidelines for referral are given in 319 
Figure 6.  320 
 321 
Review of mucous membrane pemphigoid with ocular involvement   322 
This is the commonest disease causing cicatrising conjunctivitis in the UK, accounting for 60% of CC cases, and 323 
is the prototypic autoimmune mucosal scarring disease. For the latter reasons MMP has been the focus of 324 
much of the research into scarring eye diseases in developed countries and ocular involvement by MMP has 325 
threefold more citations on PubMed than any other cause of CC apart from trachoma. MMP has been the focus 326 
of most of my work in CC and is the topic of the rest of this review.    327 
 328 
Terminology  329 
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The terminology for the immunobullous diseases is confusing, given the changes in nomenclature over the past 330 
250 years, and more recently. All these bullous diseases were categorized as pemphigus, until Lever’s seminal 331 
paper in which he differentiated the intraepithelial pemphigus diseases, from the subepithelial pemphigoid 332 
(meaning “resembling pemphigus”) diseases. This separation of these diseases was based on his histological 333 
studies demonstrating the tissue that was the focus of the inflammatory response. Since then the 334 
immunobullous diseases have been classified into these two groups, which are described in Figure 5.  335 
 The terminology for MMP has also changed. Initially Lever’s term for this was Benign Mucous Membrane 336 
Pemphigoid (BMMP) because, unlike pemphigus vulgaris, which had a very high mortality before the 337 
introduction of steroids, it was rarely fatal. In the 1980’s the term BMMP was replaced by the term cicatricial 338 
pemphigoid (CP) to reflect the associated scarring. CP and MMP have been used interchangeably at different 339 
times, and the studies describing the sites of involvement have prefaced these terms with the name of site, 340 
most often ocular CP (OCP) and ocular MMP (OMMP). Cicatricial pemphigoid is a term that is now used to 341 
describe a rare disease, having the same immunopathology as MMP, but which is limited to the head and neck 342 
and is also called localised CP or Brunsting Perry cicatricial pemphigoid58. The term OCP is still in occasional use 343 
although, following the 2002 Consensus document44 the term MMP has been recommended for any patient, 344 
with any site of involvement (because multiple sites are often involved). However, this recommendation is 345 
impractical for specialist publications, describing the diagnosis and management of the different mucosal sites, 346 
and the descriptive terms ocular MMP (instead of OCP) and oral MMP are now being used for studies focused 347 
on diseases at these sites.  348 
 The other principal terminological difficulty is the altering nomenclature of the basement membrane 349 
immunoreactant proteins: examples are BP180, also known as Bullous Pemphigoid Antigen II and classified as 350 
Collagen type XVII, BP230 is also known as Bullous Pemphigoid Antigen I, laminin 332, formerly called laminin 5 351 
or epiligrin, and p200 protein which is now designated as laminin γ1.  352 
 353 
Clinical characteristics  354 
a. Sites of involvement: Mucous membrane pemphigoid involves all the orificial mucosal sites (oral, ocular, 355 
nasopharyngeal, genital and anal) as well as, less often, tracheal and oesophageal. The skin may also be 356 
involved. Figure 7 shows examples of disease at many of the sites involved by MMP.  All mucosal sites may 357 
become severely inflamed however scarring is rare in the oral mucosa whereas scarring is mandatory for 358 
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the diagnosis in the conjunctiva. Oral MMP, when restricted to the oral mucosa, has a relatively benign 359 
course in many patients, unlike ocular MMP. The conjunctiva is involved occurs in 70% of all MMP cases 360 
resulting in bilateral blindness in 20% of cases and severe sight loss in 30% of eyes36,39,59. In a cross 361 
sectional study (unpublished) between 2009-12 of 73 MMP patients with conjunctival involvement seen at 362 
Moorfields, 27% of patients had ocular only MMP, 26% ocular and oral, and a further 26% ocular, oral and 363 
nasopharyngeal, with the remainder having a mixture of other sites involved. 364 
b. Demographics: In the UK national incidence survey which included 50 MMP patients meeting clinical 365 
criteria for the disease the median age was 71 years (range 20-90), there was a preponderance of males 366 
with a M:F ratio of 29:21 (1.38:1), with 32/50 (64%) having extraocular MMP (as opposed to ocular only 367 
MMP) of whom 8 (16%) had another autoimmune disease and 26/40 (65%) were taking 368 
immunosuppressive therapy at a 12 month follow up4. These finding are similar to those in an institutional 369 
case series of 50 patients with a median age of 67 years (range 32-91), M:F ratio of 23:27 (0.85:1), 370 
extraocular MMP in 26/50 (52%) and 38/50 (76%) requiring immunosuppressive therapy after their initial 371 
assessment at the specialist centres39. There is no good data on racial predisposition although MMP is 372 
probably less common in Indian Asians60 and the Chinese61,62 than in Caucasians. The disease is reported in 373 
Japan.  374 
 375 
Clinical signs of disease progression  376 
Early diagnosis and initiation of appropriate treatment are essential to prevent the sight-threatening 377 
complications of the approximately 75% of ocular MMP patients with rapidly progressive disease26. Clinical 378 
signs are illustrated in Figure 8, ocular MMP typically presents with a red eye and persistent conjunctivitis that 379 
has not responded to topical therapy, or with cicatricial entropion and trichiasis, that may have failed surgical 380 
repair. About 30% of patients develop severe inflammation with limbitis leading to surface failure if 381 
uncontrolled   of patients present with acute conjunctivitis and limbitis leading to rapidly progressive scarring 382 
and surface failure if uncontrolled26. Similarly, persistent epithelial defect has a poor prognosis occurring in 383 
about 20% of patients. The remaining patients present with subacute or low grade chronic inflammation and 384 
slowly progressive scarring.  The earliest clinical sign in patients with subacute disease is often medial canthal 385 
scarring, with loss of the plica and caruncle.  Medial canthal scarring is usually an early sign of MMP and is not 386 
as frequent in conjunctival scarring due to other causes. Linear scarring in the sulcus subtarsalis (marginal 387 
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sulcus) of the upper tarsus is sometimes present early in the disease. Other signs, in order of progression, are 388 
subepithelial reticular fibrosis, infiltration of the tarsal and bulbar 63,64conjunctiva, shortening of the fornices, 389 
symblepharon and cicatricial entropion, followed by ankyloblepharon and then, subsequent to scarring of the 390 
lacrimal ductules which usually occurs late in the disease, a totally dry “skin like” eye. Figure 9 describes the 391 
events leading to morbidity and blindness in ocular MMP.  392 
 393 
Pathogenesis  394 
a. Predisposing factors. As described in the section on the demographics of MMP above the disease is 395 
probably more common in Caucasians than in Indian and Chinese Asians, although it may occur in any 396 
racial group. Also, other autoimmune diseases are more common in MMP patients. Many patients have a 397 
genetic predisposition to MMP, expressing the HLA-DQB*0301 gene65. For the majority of patients there 398 
are no identifiable precipitating factors. However, in subsets of patients, including cases of ocular MMP 399 
following SJS/TEN11,66 and topical glaucoma treatment55,67, it is possible that damage to the conjunctival 400 
basement membrane precipitates the disease by exposing basement membrane epitopes triggering a 401 
pathological autoimmune response to neoantigens. The latter mechanism is an alternative to the 402 
development of loss of tolerance to basement membrane antigens that is described below and thought to 403 
be the underlying mechanisms in most cases.   404 
 405 
b. Loss of tolerance, autoantibodies and autoreactive T cells and mechanisms of disease activation and 406 
remission at different sites in MMP. As in other autoimmune disorders disease probably develops as a 407 
result of loss of tolerance. In the case of the autoimmune subepithelial bullous dermatoses, of which MMP 408 
is one, loss of tolerance is to epithelial basement membrane proteins. This has been shown to result in 409 
circulating autoreactive T cells in 2 cases68 and in the generation of autoantibodies to a number of 410 
basement membrane proteins, most commonly BP 180, described in Figure 4. The pathogenic potential of 411 
antibodies has been demonstrated:  anti-laminin 332 induces blistering in a mouse model and anti-α6β4 412 
integrin induces separation of the dermoepidermal junction in organ culture of human skin, 9. In serum, 413 
antibody levels have been correlated with disease activity in MMP69. As a result of these findings it has 414 
been proposed that autoantibodies must be demonstrated for the diagnosis of MMP44 as for the other 415 
pemphigoid diseases9.  416 
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 On the other hand, not all patients with MMP have demonstrable circulating antibodies. In ocular MMP 417 
only 50% of patients have demonstrable autoantibodies (see section on negative immunofluorescence 418 
findings in ocular MMP, above). In addition, few MMP patients suffer from involvement of all potential 419 
sites of involvement: of 112 patients with MMP in a cross sectional study in London (unpublished) 2/112 420 
patients had 5 involved sites, and 6/112 had 4 involved sites, from a potential maximum of seven sites 421 
(ocular, oral, skin, nasopharyngeal, laryngeal, genital, perianal). The mechanisms that protect individual 422 
sites from involvement in a systemic disease, caused by circulating antibodies to proteins common to the 423 
basement membranes of all the target tissues, may involve factors local both to those tissues and to the 424 
local cell mediated inflammatory response. The latter is a feature of these diseases9,70  in which 425 
autoreactive T cells are central both to the autoantibody response, and to the cellular autoimmune 426 
response68.  Combined cellular and antibody mediated responses are common in autoimmune diseases, all 427 
of which require autoreactive T cells. Although some autoimmune diseases are dominated by the 428 
pathogenic effects of one effector pathway, either autoantibodies or effector T cells, both pathways are 429 
commonly involved. Examples are Graves’ disease which is an autoantibody dominated disease, mediated 430 
by autoantibodies to thyroid stimulating hormone. At the other end of the spectrum, psoriasis is the result 431 
of an autoreactive T cell dominated response to skin associated antigens. However, most autoimmune 432 
diseases, exemplified by  systemic lupus erythematosus and rheumatoid arthritis, result from the effects of 433 
both autoantibody and autoreactive T cell mediated  inflammation in the target tissues71.  In bullous 434 
pemphigoid there is ample evidence for combined autoimmune cellular and antibody mediated effector 435 
pathways9, as there is for mucous membrane pemphigoid72 .  436 
 Autoimmune reactivity is normal in healthy individuals who may express both autoantibodies and 437 
autoreactive T cells without developing an effector response that results in disease71. In the last decade 438 
naturally occurring autoantibodies have been shown to have homeostatic functions in the clearance of 439 
oxidatively damaged body waste, and in the modulation of immune cell functions73. Autoantibodies in 440 
normal MMP controls: several studies have examined the prevalence of autoantibodies to BP180 and 441 
BP230, the basement membrane proteins commonly precipitating an autoreactive response in pemphigoid 442 
diseases and show that these are probably present in about 10-15% of healthy age matched individuals. 443 
However, the prevalence of these antibodies has varied in relation to the sensitivity and specificity of the 444 
assay used and the control group. The lowest prevalence has been than 1% in a large cohort of blood 445 
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donors of unknown ages74, other publications have given values of 7.5%75, 13%, 16% and 26% for ELISA 446 
and or immunoblots76 although higher values have been reported77. Results for IIF have generally shown  447 
<5% positivity75,76 although this was 19% (n=32) in another study78. Autoreactive T cells recognising the 448 
basement membrane protein BP 180, are also present in healthy individuals expressing the HLA-DQB*0301 449 
gene (although not in those who did not)79. These autoreactive T cells are thought to be prevented from 450 
developing a pathological response by the activity of both regulatory T cells (Treg)80 and regulatory B cells 451 
(Breg)81. The role of these regulatory cells has been evaluated in only two studies in MMP: Treg were 452 
shown to be present in higher numbers in MMP lesional tissue compared to the skin of normal controls72 453 
whereas a study of peripheral blood in patients, with a variety of pemphigus and pemphigoid diseases, 454 
showed reduced numbers of cells with Breg characteristics, compared to controls, in pemphigus only and 455 
not in pemphigoid82.   456 
 In summary a substantial proportion of normal individuals have antibodies to both BP180 and BP230, 457 
some also having autoreactive T cells to BP180. There is evidence that Treg are present in MMP lesional 458 
tissue. We can hypothesise that differences in the balance between autoreactive T cells and Tregs in the 459 
different lesional MMP tissues account for the development and resolution of the disease in different 460 
target tissues in any one individual affected by MMP. If this occurs disease activation and remission in 461 
MMP is likely to be occurring at a local lesional level in the tissues, and independent of circulating 462 
autoantibody production and local antibody deposition. If this hypothesis is correct then the balance, 463 
between autoantibody and autoreactive cellular effector mechanisms, may differ both for different sites, 464 
and at different stages of disease chronicity, accounting for the lack of evidence of circulating antibodies in 465 
some cases of MMP, particularly in those with ocular MMP.   466 
 However, this is an area which demands further study, and the control mechanisms are likely to be 467 
more complex than this. Given that anti-CD20 B cell depletion therapy (such as the anti-CD20 monoclonal, 468 
rituximab) is effective in many cases of T cell mediated diseases such as type I diabetes and rheumatoid 469 
arthritis, as well as MMP, the role of B cells in regulating T cell responses has been examined83 and 470 
evidence suggests that, in some circumstances, B cell antigen presentation to autoreactive T cells may be 471 
necessary to develop an autoreactive T cell response. In addition, unstimulated B cells may also promote 472 
the development of Treg cells83.   473 
 474 
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Summary of the pathogenesis of inflammation and scarring in ocular MMP.  475 
This is described in Figure 10, for which the evidence is summarised both in Table 3 “Effectors and cytokines 476 
identified in MMP conjunctiva” and in the hypothesis synopsised above, that the inflammatory response is 477 
both the result of a variable balance between epithelial basement membrane autoreactive T cell mediated 478 
inflammation, in the lesional tissues, and also results from circulating autoantibodies to basement membrane 479 
proteins. Although the effects of inflammation and scarring are closely related it is easier to dissect out the 480 
mechanisms for each separately: 481 
 482 
a. Inflammation: current descriptions ascribe the inflammatory response in MMP as arising from loss of 483 
tolerance to basement membrane proteins resulting in autoreactive T cells interacting with autoreactive B 484 
cells in the regional lymph nodes. This results in the generation of plasma cells, producing IgG or IgA 485 
circulating antibodies. Antibody may also be locally produced given that plasma cells are found in the 486 
lesional tissue, whereas the evidence for the presence of B cells in lesional tissue is mixed84,85. Loss of 487 
tolerance is more common in individuals expressing HLA-DQB*0301 which may promote (restrict) the 488 
activation of T cells that are autoreactive to basement membrane proteins79. Following this IgG and/or IgA 489 
antibody binds to the basement membrane in the conjunctival mucosa, resulting in complement fixation 490 
and the development of an acute inflammatory response leading to an influx of neutrophils, macrophages, 491 
dendritic cells and both cytotoxic (Tc) and helper (Th) T cells and plasma cells84,85. MHC class II protein 492 
(required to present peptides to the immune system) are highly expressed in MMP conjunctiva85. Mast 493 
cells and eosinophils, capable of producing pro-fibrotic cytokines are also found in acute disease86. 494 
Transforming growth factor beta (TGFβ) is overexpressed in acute disease compared to controls but not in 495 
chronic disease and, although the profibrotic factors, platelet derived growth factor (PDGF) and fibroblast 496 
growth factor (FGF) are present they are not overexpressed, suggesting that in chronic disease fibroblast 497 
activity remains functionally and morphologically abnormal after the withdrawal of the influence of growth 498 
factors85,87. The B7-2 costimulatory molecule required for T cell proliferation in the presence of IL-2 is also 499 
overexpressed and can be expected to lead to increased T cell expansion84. Of the cytokines, IL-2, IFNγ and 500 
TNFα (Th1 signature cytokines) are all present although not overexpressed compared to controls85,87. 501 
However, serum TNFα, an important pro-inflammatory mediator, has been shown to be elevated in MMP 502 
compared to controls and, in a more recent study, to be overexpressed in inflamed compared to treated 503 
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MMP conjunctiva88. Evidence for the activity of Th2 cells in ocular MMP comes from the finding of 504 
elevated levels of IL-13 in inflamed MMP conjunctiva89 and IL-5 in serum86, although the latter is also 505 
produced by mast cells.   506 
 507 
b. Scarring: Profibrotic mediators have been investigated in several studies including TGFβ, PDGF, FGF and IL-508 
13 as described above. Collagen type I and III are increased in ocular MMP stromal tissue.  Cultured in vitro 509 
MMP conjunctival fibroblasts respond to TGFβ by the induction of heat shock protein 47 (HSP47), which is 510 
thought to influence procollagen synthesis and fibrosis resulting in collagen Type I production90. 511 
Macrophage accumulation in the conjunctiva is probably an important event in the pathogenesis of MMP 512 
conjunctival scarring stimulated by  macrophage derived cytokines and growth factors, including IL-4, 513 
PDGF, and TGFβ.  Increased levels of macrophage inhibition factor (MIF)91 and macrophage colony 514 
stimulating factor (m-CSF)92, have been demonstrated in both  in vitro cultured MMP fibroblasts and in 515 
whole conjunctiva and associated with increased numbers of macrophages. Connective tissue growth 516 
factor (CTGF), a downstream profibrotic mediator of TGF-β1, is overexpressed in both ocular MMP whole 517 
conjunctiva and in MMP cultured fibroblasts93. These studies demonstrate that the effector cells, cytokines 518 
and growth factors necessary for fibrosis are present in the MMP conjunctiva. However, the mechanisms 519 
that relate this inflammatory milieu to the production of the extracellular matrix (ECM) by fibroblasts, that 520 
results in scarring, have not been identified 94-96. However, our recent studies outlined below have 521 
identified one control mechanism.   522 
 We have previously confirmed that OMMP fibroblasts maintain a profibrotic phenotype in vitro and 523 
have hypothesised that progressive fibrosis may be precipitated by the inflammation associated with 524 
ocular MMP, and then persist in eyes having clinical control of inflammation because of the continuing 525 
activity of persistently profibrotic fibroblasts 97. In recently published studies98 we have identified that the 526 
aldehyde dehydrogenase (ALDH)/retinoic acid (RA) metabolic pathway regulates this profibrotic activity in 527 
ocular MMP conjunctival fibroblasts in vitro. We have shown that ALDH is overexpressed in ocular MMP 528 
conjunctiva at the gene and protein level, compared to controls, and that ALDH inhibition with disulfiram 529 
abolished the profibrotic phenotype in MMP conjunctiva, resulting in the adoption of a normal control 530 
phenotype. Conversely in vitro fibroblasts from normal controls adopt a profibrotic phenotype when 531 
treated with RA, the metabolic product of ALDH. These findings provide evidence for ALDH/RA 532 
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autoregulation in ocular MMP fibroblasts as a mechanism underlying progressive conjunctival scarring 533 
seen in this disease and the potential for ALDH inhibition with disulfiram as a therapy for fibrosis. These 534 
findings were further confirmed in a mouse model of ovalbumin induced severe conjunctival inflammation 535 
that was developed for allergic eye disease studies in which we have shown that conjunctival scarring 536 
develops concurrent with inflammation. ALDH inhibition in this model, using topical disulfiram, was 537 
effective in preventing scarring in vivo, and also restored in vitro in mouse conjunctival fibroblasts to a 538 
normal phenotype, as in ocular MMP. Furthermore, another paper published with this study, has shown 539 
that in the same mouse model conjunctival scarring is initiated by the key role of dendritic cells, through 540 
paracrine production of ALDH/RA effecting conjunctival fibroblasts99.  Given our hypothesis that the 541 
scarring in ocular MMP is the result of the inflammatory response in MMP, rather than due to the 542 
autoimmune pathogenesis per se, we believe this mouse model provides a surrogate for studying immune-543 
mediated conjunctival scarring. Disulfiram is a drug already licensed for alcohol abuse control. These 544 
studies suggest that it could be repurposed for the topical treatment of conjunctival scarring in ocular 545 
MMP and provide justification for a randomized controlled trial of disulfiram therapy in this disease. Other 546 
mucosal scarring diseases are potential targets for further study using these techniques. Conjunctival 547 
diseases that may share these fibrotic mechanisms are Stevens-Johnson syndrome, atopic 548 
keratoconjunctivitis and trachoma. 549 
 Although ALDH inhibition is effective in these models we do not understand the molecular 550 
mechanisms underlying these profibrotic effects of ALDH/RA. It is possible that these profibrotic effects 551 
are mediated by similar mechanisms to those described in liver fibrosis 8,9, by the induction of the TGFβ1 552 
gene, and/or activation of latent TGFβ1, for example by increased plasminogen activator levels. Active 553 
TGFβ drives critical changes in fibroblast metabolism, activation and ECM production in concert with pro-554 
inflammatory cytokines and growth factors that affect fibroblast activity10. Alternatively, ALDH/RA might 555 
cause its effects through altered cellular energy metabolism via activation of TGFβ or as a consequence of 556 
the modulation of the transcription of metabolic genes11. The ALDH/RA metabolic pathway and these 557 
potential molecular mechanisms are described in Figure 10.  558 
 559 
Treatment summary 560 
a. Treatment outcomes for ocular MMP before 1980  561 
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These were poor until the 1980’s when immunomodulation techniques were introduced for their 562 
management for the first time. In the first series of cases reported by Morris in 1889 the outcomes were 563 
summarised: 28 cases (12F, 13M) onset from infancy to 76 years. “Disease began in the skin in 16, other 564 
mucosae in 4, and in the eye in 8. Twelve cases had conjunctival blistering, and others a pseudomembrane, 565 
entropion, progressive conjunctival shrinkage, cloudy cornea, thickened bulbar conjunctiva and 566 
xerophthalmia. Generally, vision is lost apart from perception of light although corneal perforation and 567 
destruction of the globe has been reported. One case had been described with spontaneous remission. 568 
Entropion surgery and application of lotions for the inflammation are palliative, there is no treatment for 569 
the progressive scarring. The pathology is obscure. It is a very rare disease”104. In Swanzy’s 1895 textbook 570 
he stated “Treatment is helpless in respect of arresting the progress of disease, or of restoring sight when 571 
lots in consequence of it. The most one can do is to relieve the distressing symptoms by emollients to the 572 
conjunctiva, and by the use of closely fitting goggles, to protect from wind, dust and sun. Internally arsenic 573 
is indicated105.” By 1951 Sorsby, in Systemic Ophthalmology stated of ocular pemphigus “Treatment is 574 
uniformly unsuccessful”106. The first textbook I owned when I started ophthalmology in 1978 was Parsons’ 575 
Diseases of the Eye 16th Edition in which it was stated that in the treatment of Benign Mucous Membrane 576 
Pemphigoid  “Local treatment is unavailing as also, indeed, is general treatment”107. The use of dapsone 577 
for the management of pemphigus and pemphigoid was introduced in the 1970’s, but not for ocular MMP 578 
until 1982108.  Systemic steroids for the control of acute disease in ocular MMP was described by Mondino 579 
in 1979109 . The first use of immunosuppressive therapy, with azathioprine and cyclophosphamide, was 580 
described by Foster for 2 cases in 1980110, followed by a larger series using these drugs in 1982111. 581 
Subsequent publications have proliferated and are described below.  582 
 583 
b. Current treatment 584 
Successful management of disease demands the integration of the following: 585 
(1) Control of surface disease  586 
i. Blepharitis 587 
ii. Dry eye 588 
iii. Corneal punctate epitheliopathy 589 
iv. Keratinisation 590 
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v. Trichiasis, entropion and lagophthalmos 591 
vi. Persistent epithelial defects 592 
vii. Corneal perforation 593 
viii. Iatrogenic toxicity 594 
(2) Control of immune mediated inflammation with systemic immunomodulation 595 
(3) Control of fibrosis 596 
(4) Prophylaxis of corneal ulceration and exposure   597 
(5) Improving vision in patients with corneal blindness 598 
 599 
The ocular surface disease management, and a synopsis of management with systemic 600 
immunomodulatory therapy, and visual rehabilitation, has been discussed in detail in two reviews from 601 
our group63,64 and a further recent review has summarized the use of immunomodulatory therapy in 602 
detail57. In this publication I have restricted the description of treatments to a summary of the role of 603 
immunomodulatory techniques and the evidence for their use in ocular MMP, with guidelines for their 604 
use.  605 
 606 
Use of systemic immunomodulation to control immune mediated inflammation  607 
a. Lack of effect of topical immunosuppressive therapy in ocular MMP. Topical steroid treatment is ineffective 608 
in controlling progressive ocular MMP, offering only variable symptomatic relief59,109. Its adverse effects of 609 
cataract and glaucoma generally outweigh the benefits. Subconjunctival steroids may be temporarily 610 
effective, but relapses occur when the injections are stopped109 and prolonged use also leads to cataract 611 
and glaucoma. Anecdotally, topical steroid will relieve discomfort and inflammation in some patients with 612 
mild/moderate disease activity but has not reduced the activity of severe inflammatory disease or the 613 
progression of scarring. Topical ciclosporin has been used in only 4 reported cases of whom 2 had some 614 
response112; we have little experience with this for ocular MMP and it is probable that the poor results 615 
reported for systemic therapy with ciclosporin may have inhibited further investigation of this modality. As 616 
a result, systemic immunomodulatory therapy is currently the standard of care for these MMP patients 617 
46,113,114.  618 
 619 
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b. Evidence for the effect of systemic immunosuppression on progression of disease. The primary goals of 620 
treatment of ocular MMP are to control inflammation and arrest fibrosis, in order to prevent progression 621 
of disease to more advanced stages and blindness. Most cicatrisation is occurs during active 622 
inflammation109, but despite control of inflammation in 70% -78% of patients with systemic 623 
immunosuppression, progressive fibrosis was still observed in 61/115 (53%)36 and 23/54 (42%)39 of 624 
patients .  Without treatment, conjunctival scarring in ocular MMP progresses in 13/20 (64%) of patients 625 
over 10 to 53 months115 . Progression is more frequent in the advanced stages of disease116.  Use of 626 
immunosuppressive therapy has been shown to slow progression of disease in one case series 116 and 627 
control of inflammation has been shown to prevent progression in one RCT 46. With current 628 
immunosuppressive regimens, progression of cicatrisation has still been observed in 10 to 53% of ocular 629 
MMP patients116-118 and is more rapid in patients <60 years of age119. A subset of MMP patients with ocular 630 
involvement have ongoing conjunctival fibrosis without overt clinical signs of inflammation120.  However, 631 
despite the absence of clinical signs of inflammation, there may still be significant cellular infiltrate on 632 
histological evaluation (“white inflammation”)87,100,121. Further systemic immunosuppression with potential 633 
systemic toxicity may not necessarily be helpful in these cases, for whom more specific local therapy 634 
targeting the cellular infiltrate or fibrogenic process would be ideal. There is evidence for both ongoing 635 
residual subclinical inflammation89,122 and transformed profibrotic fibroblasts97 as the putative drivers of 636 
scarring which progresses, despite apparent clinical control of inflammation with systemic 637 
immunosuppression. No current medical therapy is able to reverse the cicatrisation or ocular surface 638 
problems once they have developed.   639 
 640 
c. Criteria for initiating immunosuppressive therapy. About 25% of OcMMP patients do not require 641 
immunosuppression117 as they have few symptoms, limited scarring, mild or no inflammation and slow 642 
progression, or are in remission. In end-stage “burned out” disease, immunosuppression is also 643 
unnecessary as eyes are usually comfortable, albeit blind, and treatment only slows scarring without 644 
significantly reversing it. In these patient groups, if conjunctival incision surgery is planned, such as that 645 
required for cataract extraction when the fornices are very short, or before fornix reconstruction, then 646 
immunosuppression should be started beforehand, to prevent an exacerbation of postoperative 647 
inflammation and scarring which may be severe, and will result in a poor surgical result and disease 648 
 23
progression. For cataract surgery through a clear corneal incision, without conjunctival surgery123 or fornix 649 
incision for subtenon’s anaesthesia, and for lid surgery without a conjunctival incision, it is not necessary in 650 
my experience, to introduce preoperative immunosuppressive therapy.   651 
 652 
d. Identifying  inflammation due to underlying disease rather than to the secondary effects of a poor ocular 653 
surface. Identification of inflammation that is primarily due to the disease process in MMP, rather than to 654 
inflammation secondary to the effects of ocular surface disease or topical drug therapy, is essential before 655 
initiating immunomodulatory therapy. This is rarely a problem in those patients presenting with more 656 
severe disease. However, it can be difficult in those with less severe inflammation. It is necessary to 657 
differentiate inflammation due to the associated surface disease (dry eye, blepharoconjunctivitis, and lash 658 
abrasion), from immune mediated inflammation.  Clinically this can be done by evaluating the degree of 659 
bulbar conjunctival inflammation under the upper lid, which is free of the worst effects of surface disease. 660 
However sectoral inflammation, although not common, does occur and may affect any quadrant of the 661 
bulbar conjunctiva as shown in Figure 11. Topical drop toxicity/allergy, typically resulting from glaucoma 662 
medications or preservatives may cause diffuse inflammation and be impossible to distinguish from that 663 
causes by MMP unless the topical therapy is discontinued: it takes 1-2 weeks for this to start to improve 664 
after withdrawing glaucoma medication, and any other topical drops, apart from non-preserved saline (see 665 
Section 3).   666 
 667 
e. Evidence for the efficacy of different immunosuppressive regimens in controlling inflammation and 668 
guidelines for its delivery. Evidence for the effect of current immunosuppressive therapy in ocular MMP is 669 
summarised in Table 4 and comes from cohort studies124,125, interventional and retrospective case 670 
series63,108,116,126-134 and two randomized trials46.  These have indicated a role for dapsone, sulfasalazine or 671 
sulphapyridine for mild to moderate inflammation, azathioprine, mycophenolate or methotrexate for 672 
moderate inflammation, or for disease not responding to sulphonamide therapy, and cyclophosphamide 673 
with a short course of prednisolone, for severe inflammation. Combinations of sulfas and 674 
myelosuppressive drugs (methotrexate, azathioprine, mycophenolate, and cyclophosphamide) with or 675 
without prednisolone can be effective. Notes on the use of these drugs, as “step up and step down 676 
therapy”, including combination therapy as favoured by UK specialists, are in Table 4 and Figure 12. 677 
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Supplementary Appendix 4 includes a synopsis of immunosuppression management guidelines for use in 678 
clinic.   679 
 680 
f. Remission and when to stop therapy. Once complete control of inflammation has been achieved we 681 
continue immunomodulation, if well tolerated, for at least 12 months.  Following this, the dose is reduced 682 
and can be stopped, if the patient wishes, providing they understand that it will need to be recommenced 683 
if disease activity recurs.  Life-long follow-up is necessary, because disease recurs in up to 1/3 of 684 
patients129. Our series of 115 patients showed remission without therapy of at least 6 months in 20 (17%) 685 
of patients with a relapse in 4/20 (20%). In our experiences long term remissions are uncommon using 686 
conventional drug therapies. However, Thorne et al. using high dose cyclophosphamide and prednisolone, 687 
achieved better remission rates, of at least 3 months without therapy, in 40/44 (91%) within 2 years of 688 
initiating therapy, followed by an 8/40 (20%) relapse rate. However, we think the risks of adverse effects 689 
outweigh the benefits as they require cumulative cyclophosphamide doses which probably exceed safe 690 
levels for the development of malignancy (see Table 4, rows 14 and 19).  691 
 692 
The last thirty years and horizon scanning for the next decade 693 
In the last 30 years there have been great advances in the understanding of the pathogenesis and  therapy of 694 
three of the commonest causes of conjunctival scarring: trachoma159, mucous membrane pemphigoid64 and 695 
atopic keratoconjunctivitis5. These include the introduction of mass azithromycin delivery for trachoma control 696 
and the understanding that the scarring response in trachoma is only indirectly related to the precipitating 697 
infection resulting from the secondary profibrotic effects of infection.  The unravelling of the pathogenesis of 698 
atopic keratoconjunctivitis and the randomised controlled trials, demonstrating the effectiveness of topical 699 
ciclosporin in its management. For ocular mucous membrane pemphigoid, the introduction of effective therapy 700 
with systemic myelosuppressives, currently the standard of care, had only just been introduced 30 years ago 701 
before which a majority of patients progressed to bilateral blindness. There was minimal understanding of the 702 
pathogenesis of MMP at that time and what we now know is feeding into the application of new therapies for 703 
inflammation. The latter include the use of monoclonal CD20 mediated B cell elimination, and the potential 704 
development of anti-scarring therapies. There are 4 areas in particular where advances can be expected to 705 
contribute substantially to improved outcomes for patients: improved diagnostic tests, the identification of 706 
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biomarkers of disease activity, the further development of biological drugs for therapy, and the development 707 
of topical therapies for both inflammation and scarring. 708 
 709 
a. Better diagnostics 710 
The limitations of the current reliance on the detection of autoantibodies for disease identification, 711 
particularly for ocular MMP, but also for MMP affecting other sites, have been outlined above. We 712 
have some preliminary data using short peptides of BP180 that appear to be more sensitive than 713 
currently available substrates for the identification of autoantibodies in ocular MMP. An alternative 714 
approach has been used for the investigation of trachoma phenotypes using genetic biomarkers, that 715 
are up and down regulated during the inflammation, scarring and resolution160,161. A similar approach 716 
in MMP, and other causes of CC, may be expected to provide an alternative route to autoantibody 717 
detection, for both diagnosis and for the assessment of disease activity. 718 
 719 
b. Biomarkers of disease activity 720 
More objective biomarkers than clinical slit-lamp examination are needed to identify for both 721 
inflammatory and scarring activity, to help identify the effects of therapy and guide their initiation and 722 
withdrawal. Some progress has been made using neutrophils and their products for this100,101. 723 
Expression of genes that are up and down regulated in inflammation and scarring may also be worth 724 
investigating for this purpose.   725 
 726 
c. Biological drugs for MMP  727 
Conventional non biological immunomodulatory therapy with cyclophosphamide is effective anti-728 
inflammatory therapy from between 80% to 92% of cases in the larger series. However, the CD20 729 
monoclonal Rituximab has been increasingly used as rescue therapy for patients with severe ocular 730 
MMP who have failed cyclophosphamide therapy and with combined success rates of 80% in this 731 
group. Although efforts have been made to carry out a randomised trial of this drug in ocular MMP 732 
the cost of therapy has prohibited this, and manufacturers have been unwilling to support research 733 
into an orphan indication. However, there are numerous CD20 monoclonal biosimilars in development 734 
and it is probable that these drugs will become available for prospective case series, and randomised 735 
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controlled trials. The latter are needed to establish the effect of this drug in a number of areas. These 736 
include the effect in early ocular MMP, as opposed to unresponsive later stage disease.  The length of 737 
remission, evidence for the induction of tolerance to autoantigens, and the identification of 738 
responders and non-responders needs to be investigated, as has been done in pemphigus162. The 739 
optimum treatment regimen needs to be established, and the side effect profile compared to that of 740 
the other drugs used in this, relatively elderly, patient group having MMP.  741 
 742 
d. Topical therapies for inflammation and scarring 743 
There is an unmet need for effective topical therapies for inflammation and scarring to eliminate the 744 
morbidity associated with the side effects of systemic therapies. There are potential new topical 745 
therapies for both scarring and inflammation in CC. We have outlined the evidence for a promising 746 
new therapy, using ALDH inhibition, which has the potential to control scarring with topical therapy. 747 
ALDH inhibition is also in development elsewhere as an anti-inflammatory therapy for allergic eye 748 
disease and anterior uveitis. Rapidly effective anti-scarring therapy for CC is critical in preventing 749 
morbidity, given the speed of scarring during severe inflammatory episodes which take 2-4 months to 750 
resolve with current anti-inflammatory therapies in ocular MMP, and which are also very rapid in 751 
diseases like Stevens-Johnson syndrome. The latter is another additional target disease for topical 752 
anti-scarring therapy which will be effective during acute phase inflammation, when most of the 753 
scarring occurs. Perfenidone is a new class of immunosuppressant with anti-inflammatory and 754 
antifibrotic effects. Its mechanisms of action are not fully established. In different model systems it 755 
has been shown to abrogate TGF-β1-stimulated collagen synthesis by inhibiting the upregulation of 756 
HSP47 and Col1 RNA, it blocks the proliferative effects of PDGF; reduces fibroblast proliferation and 757 
downregulates the proinflammatory cytokines, TNFα, IFNγ, IL-1B and IL-6163. Topical application has 758 
been studied in human scleroderma164 and in glaucoma scarring models165. Lastly, the topical use of 759 
anti-inflammatory monoclonal antibodies, such as the anti TNFα drugs which could be given 760 
subconjunctivally, should be evaluated.   761 
 762 
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Although a lot has been done in the last 30 years, the tools for understanding the pathogenesis of these 763 
diseases have expanded exponentially, and the potential for new therapies has seldom been greater, for 764 
patients cursed with these diseases.  765 
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Legends for Figures  1 
Figure 1 2 
Portrait of Sir William Bowman by George Watts painted about 1865.  3 
I am grateful to Rachel Clarkson, Sir William’s great-great-granddaughter, for providing this image. 4 
 5 
Figure 2 6 
Illustrations of some of the causes of cicatrising conjunctivitis  7 
A. Mucous membrane pemphigoid, B. Trachoma, C. Adenovirus, D. Sebaceous carcinoma, E. Ocular surface 8 
squamous neoplasia, F. Ectrodactyly Ectodermal Dysplasia Cleft Lip/Palate  G. Glaucoma drops, H. Atopic 9 
keratoconjunctivitis, I. Stevens-Johnson syndrome, J. Ocular rosacea, K. Lichen Planus, L. Sarcoid. 10 
 11 
Figure 3 12 
The diagnostic problem in cicatrising conjunctivitis 13 
This Figure illustrates the classification of CC used in Table 2 with notes on the prevalence, which causes are 14 
often overlooked, which are usually known but which may co-exist with mucous membrane pemphigoid and 15 
causes associated with systemic diseases that may have their first manifestations in the eye.  16 
 17 
Figure 4 18 
The epithelial basement membrane structure and immunofluorescent tests 19 
The cartoon describes the basement membrane (dermoepidermal junction) structure and its constituent 20 
proteins. The proteins that have been shown to be target antigens in MMP are listed. The position of the 21 
basement membrane (BM) is shown on a direct immunofluorescence (DIF) specimen which also shows positive 22 
immunofluorescence to IgG in the BM zone. An example of indirect immunofluorescence (IIF) on salt split skin 23 
is also shown demonstrating positive fluorescence to the floor (see Figure 5). The cartoon is reproduced with 24 
permission from Figure 1 Schmidt, E. & Zillikens, D. Pemphigoid diseases. Lancet 381, 320-332 (2013).  25 
 26 
Figure 5 27 
Autoimmune bullous dermatoses and lichen planus 28 
Direct immunofluorescence (DIF) and indirect immunofluorescence 29 
 2
The illustrations in the top left panel shows pemphigus vulgaris (PV) with DIF on perilesional skin showing 30 
intraepithelial antibody binding.  In the top right panel the skin lesions in bullous pemphigoid are shown for 31 
comparison with those in PV together with an example of a positive DIF in conjunctiva with antibody binding at 32 
the basement membrane. The pemphigus and pemphigoid diseases are listed separating those that may be 33 
associated with conjunctival scarring and those that are not. The panel on mucosal lichen planus shows the 34 
typical appearance of a “shaggy” fibrin staining band at the dermoepidermal junction. The bottom panel shows 35 
indirect immunofluorescence on human salt split skin from a patient with MMP.  36 
 37 
Figure 5 38 
The spectrum of disease in mucous membrane pemphigoid (MMP) 39 
A. Gingival inflammation and ulceration, B. Palatal inflammation and ulceration, C. Supraglottic inflammation 40 
and scarring, D. Oesophageal stenosis, E. Skin ulceration and scarring, F. Foreskin scarring, G. Conjunctival 41 
inflammation and scarring, H. Intraoperative photograph showing a normal subconjunctival space under 42 
incised severely scarred and shortened conjunctiva demonstrating that subconjunctival tissue is unaffected.   43 
 44 
Figure 6 45 
Criteria for referral 46 
Criteria for referral of patients with cicatrising conjunctivitis to a specialist ocular surface disease service. 47 
Adapted from Figure 5 in Williams, G.P et al. Eye (Lond) 25, 1207-1218 (2011). 48 
 49 
Figure 6 50 
Ocular mucous membrane pemphigoid (MMP) 51 
Clinical signs in ocular MMP 52 
 53 
Figure 7 54 
Factors contributing to progression of disease in ocular mucous membrane pemphigoid (MMP) 55 
 56 
Figure 8 57 
 3
Summary of the pathogenesis of inflammation and scarring in ocular MMP 58 
This illustrates the description in this section in the text, for which the evidence is summarised in Table 3. In 59 
brief a loss of tolerance to mucosal epithelial basement membrane proteins results in the development of 60 
pathogenic autoreactive T cells (aT) which help autoreactive B cells (aB) to proliferate in the regional lymph 61 
nodes, and differentiate into plasma cells. The latter produce circulating IgG and IgA autoantibodies to the 62 
mucosal basement membrane, which are detectable in the serum of some patients by indirect 63 
immunofluorescence (and other antibody specific assays). Plasma cells are also found in the conjunctival 64 
mucosal substantia propria where they may produce local antibody. In the mucosal epithelium direct 65 
immunofluorescence tests may show the presence of IgG and/or IgA fixed to the basement membrane where 66 
C3 (complement 3) is also identified in some patients. Activation of C3 at the basement membrane precipitates 67 
the complement cascade and acute inflammation at the basement membrane. This is the injury and 68 
inflammation phase of the disease causing an accumulation of inflammatory effector cells (neutrophils, 69 
dendritic cells, mast cells, eosinophils, macrophages and T cells) and the associated cytokines and growth 70 
factors IL-2, IL-5, IL-13 (interleukins-) IFNγ (interferon gamma, TNFα (tumour necrosis factor alpha), resulting in, 71 
often severe, inflammation and expansion of both Th1 and Th2 cells into a chronic inflammatory response.  72 
 An alternative effector pathway may be more important, in the absence of autoantibody, in some 73 
subsets of patients whereby autoreactive T cells to basement membrane components home in on the mucosa. 74 
Her they can create an inflammatory response, in the absence of antibody, through their cytokines and growth 75 
factors including IFNγ, TNFα, IL-4, IL-5 and IL-13.  76 
 This inflammatory response results in fibrosis through the effects of profibrotic mediators released by 77 
macrophages, T cells, mast cells and eosinophils on fibroblasts, including PDGF (platelet derived growth factor), 78 
IL-13, TGFβ (transforming growth factor beta) and HSP47 (heat shock protein). Fibrosis also results from 79 
ALDH/RA (aldehyde dehydrogenase/retinoic acid) mediated paracrine effects of dendritic cells that activate a 80 
profibrotic phenotype in fibroblasts. During both active inflammation, and once inflammation has resolved, the 81 
activated MMP fibroblasts continue to scar as these remain profibrotic because of an ALDH/RA mediated 82 
autocrine effect. The latter probably results in RA dependent TGFβ activation and or induction, further driving 83 
fibrosis.    84 
 85 
Figure 9 86 
 4
Sectoral conjunctival inflammation in ocular mucous membrane pemphigoid (MMP) 87 
The same eye of a patient showing the superior bulbar conjunctiva free of inflammation but a localised area of 88 
inflammation in the inferior bulbar conjunctiva. 89 
 90 
Figure 10 91 
Immunosuppression for ocular mucous membrane pemphigoid (MMP) 92 
This illustrates “step up” and “step down” therapy to control conjunctival inflammation as described in the 93 
section on Evidence for the efficacy of different immunosuppressive regimens in controlling inflammation and 94 
guidelines for its delivery and in Table 4 Row 34, and Saw VP 200836.  95 
a. Drugs in different coloured boxes can be combined. The drugs in the dark red boxes 96 
(cyclophosphamide, mycophenolate, azathioprine and methotrexate) are all myelosuppressives: 97 
combining these results in unacceptable toxicity. Some authors have described the use of CD 20 98 
inhibitors (such as Rituximab) with existing myelosuppressive therapy for unresponsive ocular MMP153  99 
but this may be unsafe and we follow the recommendations of restricting adjunctive drugs to sulfas146 100 
and stop the myelosuppressives immediately before the first CD20 monoclonal infusion. Prednisolone 101 
can generally be given for a short term effect with any of the other drugs listed but is usually needed 102 
in high doses, with its associated side effects.  103 
b. In general, all of these drugs, except high dose steroids take 2-4 months to take effect. This period is 104 
probably shorter for the CD 20 monoclonals than the other drugs. A full effect will often take longer 105 
and for this reason, unless inflammation is deteriorating, I do not usually alter therapy for 12 weeks.  106 
c. For mild/moderate ocular MMP use step up therapy. Start with a sulfa and, there is no effect, or 107 
toxicity, introduce mycophenolate. If the effect is limited but the drug is tolerated, add 108 
mycophenolate to the sulfa. Azathioprine (in grey typeface) is the second line drug when 109 
mycophenolate is not tolerated and methotrexate (in grey typeface) the third line drug in this 110 
situation because these are generally less well tolerated than mycophenolate and no more effective. If 111 
none of these drugs works switch to cyclophosphamide without using adjunctive steroid unless the 112 
patient is deteriorating. Failing these then a CD20 monoclonal is the next choice of drug and, if there is 113 
a lack of response to that 2 months after a second cycle of therapy, then start IV immunoglobulin 114 
therapy.  115 
 5
d. For severe MMP (severe conjunctival inflammation +/- limbitis +/- corneal ulceration) use step down 116 
therapy. Start oral Prednisolone 1 mg/kg WITH cyclophosphamide 1.0-1.5 mg/kg. Very severe cases 117 
will get a short term benefit from intravenous methylprednisolone 1 gram IV daily for 3 days before 118 
starting oral prednisolone with cyclophosphamide (unpublished data). If cyclophosphamide and 119 
prednisolone are not effective within 2-3 months, add a sulfa and then switch to a CD20 monoclonal. 120 
If this fails, as in the previous example, then start IVIG. Once control of inflammation has been 121 
established the patient can start stepdown therapy.  122 
i. For cyclophosphamide follow the toxicity guidelines in Table 4 row 19, I usually maintain 123 
therapy for up to 12 months in the hope that a longer period of therapy might induce a 124 
remission. Two months before discontinuing cyclophosphamide, introduce a sulfa, if 125 
tolerated. After discontinuing cyclophosphamide patients with full control of inflammation 126 
can discontinue sulfas after another 2-4 months therapy. For patients with partial control the 127 
sulfa is maintained and mycophenolate (azathioprine or methotrexate) added. Drugs can be 128 
discontinued as required dependent on disease control and the development of side effects. 129 
ii. After CD 20 monoclonals patients may be in remission and any sulfa therapy can be 130 
discontinued after 2-4 months therapy. In the event of a relapse a decision has to be made 131 
whether to control this with step up therapy or a further cycle of a CD 20 monoclonal.  132 
iii.  After IVIG patients will usually still be in myelosuppressive agents which can be stepped 133 
down or stepped up as described above.  134 
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treatment responses in these patient groups do not 
diﬀ er greatly from those in adults.12
Mortality, risk factors, and associated diseases
1-year mortality for patients with bullous pemphigoid 
ranges from 20% to 40%, which is about two to 
three times higher than that of age -matched and sex-
matched controls.9,10,13 Old age, widespread disease, a low 
Karnofsky score, and, importantly, high doses of oral 
corticosteroids are key risk factors for death.14,15 Patients 
with bullous pemphigoid are also three times more likely 
to develop pneumonia and pulmonary embolism than 
are matched controls.10
In the past 5 years, researchers have learned of an 
association between bullous pemphigoid and neuro-
logical disorders. Between a third and half of all bullous 
pemphigoid patients have neurological diseases (odds 
ratios from 2·4 to 10·6).16–19 In particular, major cognitive 
impairment, Parkinson’s disease, stroke, epilepsy, and 
multiple sclerosis have been associated with bullous 
pemphigoid in controlled studies.16–19 These fi ndings are 
especially intriguing since both bullous pemphigoid 
target antigens, BP180 (also termed type XVII collagen, 
COL17, or bullous pemphigoid antigen 2, BPAG2) and 
BP230 (dystonin or BPAG1), are expressed in the central 
nervous system. BP180 expression has been reported in 
the cerebellum of rats and in autopsy samples of various 
neuroanatomical regions of human brain,20,21 and the 
antigen is predominantly seen in lipofuscin granules of 
ageing, post-mitotic neurons.20 Mice with mutations in 
the dystonin gene that encodes for various isoforms of 
BPAG1, including the epithelial isoform BP230, develop 
severe dystonia and sensory nerve degeneration.22
Investigators discovered an independent association of 
bullous pemphigoid with psoriasis in a population-based 
study based on data from the national health insurance 
database in Taiwan.17 Various autoimmune disorders and 
cancer have also been linked with the disease. However, 
investigators of a case-control study23 did not report any 
increased risk for other autoimmune disorders and 
investigators of two case-control studies into bullous 
pemphigoid and cancer risk reported no association24 or 
only a weak association with gastric cancer25 in Swedish 
and Japanese cohorts, respectively, compared with age-
matched controls.
Several triggers have been implicated in disease onset 
in individual patients, including trauma, burns, radio-
therapy, ultraviolet radiation, and vaccination—most 
frequently against infuenza.26,27 Investigators of two 
studies reported weak but signifi cant associations with 
chronic use of spironolactone and phenothiazines with 
aliphatic side chains,19,28 so use of these drugs should be 
carefully assessed by prescribing physicians.
Clinical presentation
Bullous pemphigoid typically presents with tense, mostly 
clear, blisters and erythema, frequently in con junction 
with urticarial plaques (fi gure 2). Blisters often arise on 
the fl exural aspects of the limbs and on the abdomen and 
can persist for several days, leaving erosions and crusts. In 
almost all patients, severe pruritus is present. Mild oral 
lesions develop in 10–20% of patients, but other mucosal 
areas are rarely aﬀ ected.29 Before development of blisters, 
the disease is typically preceded for several weeks and 
even months by a prodromal phase in which pruritus 
alone or in association with excoriated, eczematous, and 
papular or urticarial lesions occur (fi gure 2). In some 
patients, these non-bullous skin symptoms persist and are 
defi ned as several clinical variants—eg, prurigo-like, 
erythroderma-like, ecthyma gangrenosum-like, intertrigo- 
like, and toxic epi dermolysis-like bullous pemphigoid.29 
Localised forms of the disease frequently aﬀ ect the 
pretibial area. In 2011, an international panel of experts 
defi ned outcome measures for clinical studies and 
developed a clinical scoring system, the BP Disease Area 
Index,30 to allow comparisons of clinical trials. This index 
will need further validation.
Target antigens
Two hemidesmosomal proteins, BP180 and BP230, 
have been identifi ed as target antigens in bullous 
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Further	examples	of	DIF	and	IIF	are	shown	in	Figure	5
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Table 1 
Institutional and national surveys of cicatrising conjunctivitis 
 
Institutional case series of cicatrising conjunctivitis 
(CC) Thorne JE 20043. Includes 74 cases of cicatrising 
conjunctivitis caused by Mucous membrane 
pemphigoid (MMP) and 145 caused by other diseases 
UK national survey of new cases of CC 
Radford C4 n=82 
 Number (%)
74 cases of MMP 
and 145 others  
Number (%)
Total n=82 
Incidence per 
million 
MMP 74 (33.7%) 50 (60.95%) 0.8 
Other causes of CC 145 a  
Linear IgA bullous dermatosisb  None (N) 1    (1.25%)  
Topical glaucoma drug induced (28.3%) 3    (3.65%)  
Rosacea blepharoconjunctivitis (20%) 3    (3.65%)  
Atopic keratoconjunctivitis (8.3%) 3    (3.65%)  
Sjögren’s syndrome or KCSc  (7.6%) 1    (1.25%)  
Stevens Johnson syndrome  (6.3%) 16 (19.51%) 0.2 
Graft versus host disease   (1.4%) 2    (2.43%)  
Lichen planus N 2    (2.43%)  
Ocular surface neoplasia N 1    (1.21%)  
Non-trachomatous infection  (5.5%) N  
Trachoma  (2.8%) N  
Sarcoidosis  (3.5%) N  
Pemphigus vulgaris  (3.4%) N  
Paraneoplastic pemphigus  (2.8%) N  
Trauma or lid surgery  (2.8%) N  
Ectodermal dysplasia  (2.1%) N  
Chronic cutaneous lupus   (1.4%) N  
Aplasia cutis congenital  (0.7%) N  
Ectopic geographic tongue  (0.7%) N  
aPercentages of causes for the 145 cases of cicatrising conjunctivitis not caused by MMP. Percentages total 
above 100% because some patients had more than one diagnosis.    
bNow classified as MMP 
cKeratoconjunctivitis sicca 
 
 
Table 2  
Current classification of cicatrising conjunctivitis.  
Causes are underlined. Some causes appear twice because they result in either progressive or non-progressive scarring disease.  
The pemphigus and pemphigoid diseases NOT currently known to cause conjunctival scarring are also listed.   
CLASSIFICATION  Description
BLINDING SCARRING DISORDERS  Progressive inflammatory and scarring diseases for which systemic 
immunomodulation is often needed for control of scarring & inflammation 
Mucous membrane pemphigoid (MMP) 4 Currently 60% of all CC cases in the UK are caused by MMP which now includes the 
conditions mucosal dominated epidermolysis bullosa acquisita, linear IgA disease and 
anti-laminin 332 (formerly anti-epiligrin or anti-laminin 5) pemphigoid9  
Drug-induced progressive conjunctival cicatrisation10 A rare complication of topical medication, usually for glaucoma. A small subset of 
patients with these diseases develop autoantibody-positive or negative progressive 
conjunctival indistinguishable from MMP 
Stevens-Johnson Syndrome (SJS) & Toxic Epidermal Necrolysis (TEN) with 
progressive scarring11 
Only a small subset of patients with these diseases develop autoantibody-positive or 
negative progressive conjunctival scarring similar to that in MMP which may continue 
from the acute episode or develop acutely years later  
OCULAR SURFACE NEOPLASIA 
Ocular surface squamous carcinoma (OSSN)4 and sebaceous cell carcinoma12 Rare causes of conjunctival scarring and inflammation indistinguishable clinically from 
MMP, except that cases are usually unilateral   
OTHER SCARRING CONJUNCTIVAL DISEASES  
Sometimes referred to as “Pseudopemphigoid” see discussion of Thorne JE 
20043 and in section on Current causes, epidemiology and classification of 
cicatrising conjunctivitis  
Diseases that may be clinically identical at presentation with fornix shortening & 
symblepharon BUT in which scarring rarely results in blindness, although 
inflammation may be severe. MMP may occur in these diseases and should be 
excluded   
Ocular diseases with no systemic involvement
Drug induced scarring10  Usually due to topical preservatives or unpreserved glaucoma medication and, rarely, 
other drugs. Inflammation resolves after withdrawing the drops and scarring stabilizes  
Atopic keratoconjunctivitis3,5,13 Usually a tarsal papillary reaction in addition to scarring although this may be minimal 
in severe longstanding cases  
Trachoma14 Tarsal scarring typical but symblepharon occurs15
Adenoviral conjunctivitis16-18 Scarring with entropion and symblepharon are occasionally present. These patients 
must have a history of an acute severe conjunctivitis to confirm the diagnosis 
Conjunctival trauma: chemical, thermal19, surgical and radiation injury20 Diagnosis is clear from the history
Oculodermal diseases 
Stevens-Johnson syndrome and Toxic Epidermal Necrolysis21 Diagnosis clear from history. A small subset of patients develop progressive scarring 
disease see the section on Blinding Scarring Disorders above   
Pemphigoid diseases (sub-epithelial immunobullous diseases)9 Pemphigoid diseases with conjunctival scarring unreported or very rare: one case of 
anti-p200 with anti-laminin 332 pemphigoid22, lichen planus pemphigoides may 
involve oral but not ocular mucosa23, pemphigoid gestationis rarely involves mucosa 
and conjunctival involvement is unreported to my knowledge24  
Bullous pemphigoid25 Conjunctival scarring infrequent
Mucous membrane pemphigoid See Blinding Scarring Disorders above. In about 20% of cases the disease progresses 
very slowly or is in remission and systemic immunosuppression is not required26   
Paraneoplastic pemphigoid Severe scarring may occur27 
Pemphigus diseases (intra-epithelial immunobullous diseases) Pemphigus diseases in which conjunctival disease is unreported: pemphigus 
gestationis, pemphigus foliaceous (may involve lid skin but not the conjunctiva)28 and 
IgA pemphigus  
Pemphigus vulgaris29,30 Conjunctivitis occurs but scarring is rare. However, several cases have presented in the 
eye accompanied by severe scarring and corneal perforation30 
Paraneoplastic pemphigus27,29 Conjunctivitis occurs. Severe scarring may occur but is uncommon27
Dermal diseases with variable ocular involvement  
Ocular rosacea3,31 Some scarring is common 
Dermatitis herpetiformis19 Rarely causes scarring 
Lichen planus32,33 Rarely causes scarring 
Systemic lupus and discoid lupus34 Rarely causes scarring 
Multisystem disorders  
Graft versus Host Disease6 The diagnosis has usually been made by the oncologist. Conjunctival scarring and 
inflammation is common   
Sarcoid3,7 Rare but may present in the eye as severe scarring conjunctivitis
Sjögren’s syndrome and keratoconjunctivitis sicca3,4 Scarring is rare
Miscellaneous congenital and acquired disease
Ectodermal dysplasia (ED) diseases (includes ectrodactyly-ectodermal 
dysplasia-cleft syndrome (EEC) cases as well as ED8  
Some patients develop circulating basement membrane antibodies or mucosal direct 
immunofluorescence: inflammation may be severe with scarring   
Inflammatory bowel disease19 Scarring is reported but very rare 
Porphyria cutanea tarda35 Scarring is reported but very rare
 
 
Table 3  
Effectors and cytokines identified in MMP conjunctiva 
 
GLOSSARY (alphabetical in the order of the abbreviations in the Table with additional notes on origin and function  
 B7-2: a costimulatory T cell ligand expressed on dendritic cells and macrophages. 
 CD40, CD80, CD154: costimulatory molecules on T cells.  
 FGF: a family of fibroblast growth factors, including basic FGF (bFGF) produced by monocytes and important in wound repair. 
 CTGF: connective tissue growth factor produced by fibroblasts and is a downstream mediator of TGFβ1 induced collagen 
synthesis, promotes fibroblasts proliferation & enhances matrix production. 
 HSP family: heat shock proteins produced by fibroblasts and involved in the maturation of collagen   
 ICAM: intercellular adhesion molecule expressed on macrophages and lymphocytes facilitating migration into inflamed tissues 
 IFNߛ: interferon gamma, produced by activated TH1 lymphocytes, epithelia and fibroblasts with multiple roles in inflammation.
 IL-1: interleukin 1 produced by macrophages, B cells lymphocytes, fibroblasts, and endothelium is a multifunctional cytokine 
critical in initiating and maintaining inflammation and immune responses.   
 IL-2: interleukin 2, produced by T cells, and responsible for T and B cells proliferation and activation.  
 IL-4: interleukin 4, produced by mast cells, Th2 cells and fibroblasts affecting B cell, T cell and fibroblast functions with 
multiple profibrotic and inflammatory effects. Induces m-CSF, type I collagen & collagen-binding HSP47 production by 
conjunctival fibroblasts.  
 IL-5: interleukin 5, produced by mast cells, Th2 cells, eosinophils and monocytes and affects eosinophil chemotaxis, 
differentiation, activation and prolongs survival.   
 IL-6: interleukin 6, produced by macrophages, and stimulates B cells to differentiate into plasma cells 
 IL-13: interleukin 13, produced by Th2 cells, mast cells and basophils and is a potent stimulator of eosinophil, lymphocyte and 
macrophage rich inflammation and tissue fibrosis  
 m-CSF: macrophage colony stimulating factor produced by monocytes, fibroblasts and endothelial cells having effects on the 
proliferation, differentiation and activation of monocytes macrophages 
 MIF: macrophage inhibition factor produced by T cells and macrophages inhibiting macrophage migration and stimulating 
macrophage activation. 
 MPO: myeloperoxidase. This enzyme is produced and stored by neutrophils 
 MMP (in italics to distinguish the abbreviation from that for mucous membrane pemphigoid) : matrix metalloproteinase 
family of enzymes including MMP-8 and MMP-9 that degrade extracellular matrix 
 PDGF: platelet derived growth factor produced by macrophages and fibroblasts amongst others.
 Tc (Cytotoxic T cells) expressing CD8 
 TGFβ family: transforming growth factor beta, produced by many cell types (B & T cells, monocytes, macrophages, 
fibroblasts). These are profibrotic mediators with immunosuppressive effects.  
 Th1: T helper subset 1 expressing CD4 secreting their signature cytokine interferon gamma (IFN ߛ) and also producing TNFα.  
 Th2: T helper subset 2 expressing CD4 and secreting the signature cytokine IL-4 and also producing IL-5 and IL-13 
 TNFα: tumour necrosis factor alpha, produced by macrophages, mast cells and lymphocytes. It has multiple inflammatory 
functions 
Effector cells & 
proteins  
Findings in MMP Author
Circulating 
autoreactive T cells 
to BP180 
2/10 patients with MMP demonstrated IFNγ production to BP180 NC16A in peripheral 
blood mononuclear cells suggesting that this segment of BP 180 is a T cell target antigen 
in MMP 
Black AP 200468 
Neutrophils, 
macrophages, 
dendritic cells, Th 
(CD4), Tc (CD8), 
plasma cells. (TGFβ 
FGF and PDGF)  
Conjunctival biopsies from 20 patients with acute (n4) subacute (n8) and chronic (n8) 
MMP investigated showed an excess of neutrophils, macrophages and dendritic cells in 
acute disease. Increased T cells present in all subsets, with Tc:Th ratio higher except in 
acute disease when these were equal. Plasma cells increased, but not B cells or NK cells. 
PDGF, FGF and TFGß present in both diseased and controls. TFGß was overexpressed in 
acute disease. MHC class II highly expressed in diseased tissue (potential to present 
antigen to Th cells). The activated T lymphocytes were identified with anti-IL-2 showing 
these were Th1 T cells.  
Bernauer W 
199385  
Neutrophils in the 
epithelium  
 
 
Neutrophil derived 
enzymes (MPO, 
MMP-8 and MMP-
9)  
Neutrophils are elevated in the MMP conjunctival epithelium shown by impression 
cytology and increased levels are associated with progressive scarring in both inflamed 
and clinically uninflamed eyes and may be a useful biomarker of progressive fibrosis and 
response to therapy 
 
MPO is neutrophil derived, and neutrophils are also a source of MMP’s which are 
elevated in the tears of MMP patients potentially accounting for their predisposition to 
corneal melting and also potentially of use as biomarkers of disease activity    
Williams G 
2016100 
 
 
 
Arafat S 2014101 
Dendritic cells and MMP epithelium and control did not differ. Substantia propria: predominantly Tesavibul N 
T cell co-
stimulatory 
molecules 
increased increased macrophages and T cells but also Langerhans & B cells. B7-2 
costimulatory ligand (usually expressed on dendritic cells and macrophages) 
overexpressed (but not the B7-1 ligand). B7-2 overexpression may be expected to be 
associated with increased T cell proliferation via IL-2 production  
199884
Eosinophils and 
mast cells with IL-5 
in acute disease 
Serum levels of both IL-5 (produced by Th2 cells, monocytes and mast cells) and 
eosinophils were increased in MMP. Mast cell and eosinophils were increased in the 
substantia propria in MMP. Mast cells released profibrogenic cytokines in pulmonary 
and hepatic fibrosis and may be important in MMP scarring.  
Letko E 200286  
Cytokine 
expression IFNߛ 
TGFߚ, TNFߙ, PDGF  
Both diseased and normal control conjunctiva expressed IL-2, IFNߛ (Th1 signature), 
TGFߚ, TNFߙ, PDGF and bFGF as well as a proliferating cell marker. No IL-4 was 
expressed (Th2 signature). TGFߚ and proliferating cells were overexpressed in the acute 
group and IL-2, bFGF and PDGF (fibrogenic cytokines) were more expressed in the 
subacute disease group.  
Bernauer W 
1993102  
 
TGFߚ1& ߚ3 
increased 
TGFߚ1& ߚ3 increased in the stroma in association with fibroblasts and macrophages in 
acute MMP (not chronic), PDGF and FGF undetectable
Elder MJ 199787 
HSP47,  TGFβ  and 
collagen I and III  
expression in 
conjunctiva and 
role of TGFβ 1 
induction of  
HSP47 and 
collagen I by 
fibroblasts  
Collagen I & III increased in OMMP conjunctival stromal tissue, and HSP47 and TGFβ 
increased in MMP fibroblasts. TGFß1 induced HSP47 and collagen I in OMMP 
fibroblasts. Increased expression of the latter may contribute to conjunctival scarring in 
OMMP.   
Razzaque MS 
200390 
Serum TNFߙ and 
IL-6 in active MMP 
Serum levels for TNFߙ, but not IL-6, were elevated in ocular MMP patients (n=35) 
compared to controls consistent with expectations for a systemic autoimmune disease.   
Lee SJ 1993103 
TNFߙ TNFߙ is overexpressed in inflamed OMMP conjunctiva compared to treated OMMP but 
the latter still shows greater expression than control levels. TNFߙ treatment of normal 
fibroblasts stimulated increased migration, mmp-9 production, decreased timp-2 and 
timp-4 and upregulated CD40 and ICAM. CD40 may interact with T lymphocytes 
Saw VP 200988  
stimulating proliferation and profibrogenic cytokine production.   
IL-13 IL-13 is overexpressed in ocular MMP conjunctiva (both inflamed and non-inflamed) 
compared to controls. IL-13 promotes pro-fibrotic effects on normal human conjunctival 
fibroblasts and also upregulates the expression of T cell costimulatory molecules (CD80, 
CD40 and CD154) on fibroblasts potentially promoting interaction with T cells to drive 
fibrosis.  
Saw VP 2009.89
MIF protein and 
mRNA 
Increased MIF was demonstrated by immunohistochemistry and qPCR in both MMP 
conjunctiva and fibroblasts. The expression of MIF was associated with increased 
macrophage numbers.   MIF was also secreted by fibroblasts (shown by ELISA). IL-1, TNF 
and TGFβ1 induced MIF expression in fibroblasts.  
Razzaque MS 
200491 
CTGF in stroma 
and fibroblasts 
CTGF is a downstream profibrotic mediator of TGF-β1 and was overexpressed in both 
ocular MMP whole conjunctiva and in cultured fibroblasts.  
Razzaque MS 
200393  
m-CSF Macrophage colony stimulating factor (m-CSF) was overexpressed in ocular MMP 
conjunctiva, macrophages, fibroblasts and epithelial cells. m-CSF correlated with 
macrophage numbers and some macrophages expressed a proliferation marker. 
Fibroblast m-CSF expression was increased by treatment with IL-1a or TNFߙ.  
Razzaque MS 
200292 
 
 
 Table 4 
Studies on the use of immunomodulatory drugs for ocular mucous membrane pemphigoid, notes on the evidence, and guidance for the use of the drugs 
 
Row Immunosuppressive 
agent 
Author, reference 
% of patients or eyes 
responding to treatment 
Notes on the evidence and guidance on the use of the drugs
1 Nicotinamide and 
tetracycline  
Reiche L 1998135 
63% (n=8) extraocular and 2 
ocular MMP 
Small case series. Rarely used for ocular disease. I have no experience of this therapy  
2 Dapsone  
Saw VP 200836 
77% 9 (n=114) a ocular MMP Dapsone has common side effects, most often anaemia (95% of all patients to a variable extent), 
malaise and skin rashes. However, it’s not an immunosuppressive drug, may be very effective, and 
can also be combined with immunosuppressive drugs for added effect. Although unfashionable I still 
use it for these reasons. Compared to cyclophosphamide and steroid it is not as effective for severe 
disease (see below) 
3 Rogers RS 1982108 83% (n=24) extraocular and 
ocular MMP 
4 Tauber J 1991133 45% (n=69) ocular MMP
5 Foster CS 198646 70% (n=20) ocular MMP
6 Sulphapyridine  
Saw VP 200836 
65% (n=55)a ocular MMP Usually now given as sulfasalazine (in which sulphapyridine is an active agent) because 
sulphapyridine is no longer widely available. I use this as an alternative when dapsone causes 
anaemia, or is not tolerated 7 Elder MJ 1996127 50% (n=20) ocular MMP
8 Sulfasalazine  
Doan S 2001126 
45% (n=9) ocular MMP
9 Azathioprine  
Saw VP 200836 
71% (n=80)a ocular MMP Azathioprine has similar effects to mycophenolate but side effects are more common such that 
mycophenolate has largely replaced azathioprine, except as a second line agent for patients not 
tolerating mycophenolate 10 Tauber J 1991133 33% (n=11) ocular MMP
11 Ciclosporin 
Neumann R 1991132 
Foster CS 1992129 
 
2/22 patients (9%) ocular 
MMP 
Calcineurin inhibitors have generally had poor success in ocular MMP and cannot be recommended 
on current evidence 
12 Tacrolimus 
Letko E 2004130 
33% (n= 6) ocular MMP
13 Oral corticosteroids 
Hardy KM 197159 
Mondino BJ 1979109 
Foster CS 198646 
65% (n=23)b ocular MMP Doses above 0.5 mg/kg (about ≥ 40 mg) are usually needed to gain control of the disease and relapse 
is usual when doses are reduced. Side effects are unacceptable at the doses need as monotherapy 
Long term lower dose therapy has not been evaluated, but has not been needed in my patients 
having alternative steroid sparing immunosuppressive therapy. High doses (1-2mg/kg) are used for 
short term control in severe disease while the steroid sparing drug takes effect. I use a 3 months 
tapering course, usually in combination with cyclophosphamide  
14 Cyclophosphamide 
and steroids 
Thorne JE 2008134 
91% (n=44) ocular MMP This study used high dose (2mg/kg), prolonged (12-18 months) cyclophosphamide for most patients 
(68/78 or 87%). At 12 months 58/70 (83%) had complete success. However, serious complication 
rates, including malignancies (1 bladder cancers, 2 leukaemias and 6 other tumours), and 2 
pneumonias, were relatively common and probably relate to a combination of the high doses used 
and the prolonged treatment period of 12-18 months which exceed safe doses (see Row 19)  
15 Elder MJ 1995 128 15/19 eyes (79%) ocular 
MMP 
2.0 mg/kg for up to 8 months
16 Foster CS 199646 100% (n=12) ocular MMP 2.0 mg/kg 
17 Saw VP 200836 90% (n=73)a ocular MMP 1.0-1.5 mg /kg for up to 12 months 
18 Tauber J 1991133 92% (n=35) ocular MMP 2.0 mg/kg for a mean of 13 months (1-65 months)
19 Additional notes on cyclophosphamide use: 
• Cyclophosphamide monotherapy. Cyclosphosphamide is typically used for patients with severe inflammation in ocular MMP, and is recommended by all 
authors as the drug of choice for this group of patients. It is usually combined with oral steroids for rapid disease control while the cyclophosphamide 
takes effect over 2-4 months. As a result, it is difficult to establish the effect of cyclophosphamide used as a single agent: in two of these studies 14/7336 
and 2/25133 had cyclophosphamide without steroid. I use cyclophosphamide as single agent when patients have not responded adequately to other 
therapies, but do not have severe enough disease to risk oral prednisolone.  
• Cyclophosphamide dose and malignancy. The dose of cyclophosphamide is given as between 1.0-2.0 mg/kg in the different studies and reviews 
summarized in rows 14-18. However, cyclophosphamide has a wide range of serious side effects listed in the studies below. In the last decade a maximum 
safe dose below which bladder cancer, and acute myeloid leukaemia are unlikely to occur, have been established in patients treated with 
cyclophosphamide for polyangiitis with granulomatosis. The probable cumulative safe doses for bladder cancer are 25gms, or 12 months treatment136 and 
up to 36 gms, to limit the risk of both bladder cancer and acute myeloid leukaemia137.  
• How to use cyclophosphamide. Cyclophosphamide tablets in the UK are available in 50mg or 100 mg and doses other than multiples of these can only be 
given by alternating therapy e.g. 50 mg one day alternating with 100 mg the next day to give a mean daily dose of 75 mg. I now use 1.0-1.5mg/kg36 to 
restrict cumulative doses to the proposed safe limits. For most males I start with 100 mg per day for up to 12 months (a 36 gm cumulative dose for a 70kg 
person at 1.5 mg/kg). For women of 50kg I use 1 mg/kg for 12 months (an 18 gm cumulative dose over 12 months) but adjust the dose, and length of 
therapy, to get control of disease.  Most patients will need 8 months of therapy to give them a period of one or two months of controlled inflammation 
and some will need more. This is less than the dose of 2.0mg/kg quoted in all the other studies, including our early publication128, to optimize safety. After 
the cumulative safe dose is reached I usually switch to a sulfa, before stopping cyclophosphamide, and add an alternative myelosuppressive if needed 
after discontinuing cyclophosphamide. 
• Intravenous cyclophosphamide. The effects of this route have been rarely reported in ocular MMP case series: it is probably safer than daily oral therapy 
and may be as effective 138. However, for polyangiitis with granulomatosis a randomized trial of daily oral dosing versus intravenous cyclophosphamide 
(the CYCLOPS trial) showed that oral dosing was more effective in the long term139. I have no experience of this modality of administration.  
 
20 Methotrexate  
McCluskey P 2004131 
83% (n=12) ocular MMP This is the only study describing methotrexate in detail. Other large studies have not used the drug 
(0/78)134 or only in small numbers (4/115)36 ,or the effects is not clear from the publication118. I have 
little experience with this drug and use it as a third line agent when patients cannot tolerate, or don’t 
respond to, dapsone/suphasalazine, azathioprine, mycophenolate, and when cyclophosphamide 
cannot be used 
21 Mycophenolate 
Saw VP 200836 
82% (n=46)a ocular MMP Mycophenolate is one of the best tolerated and safest immunosuppressive drugs to use and is my 
first line recommendation for moderately severe disease 
22 Zurdel J 2001140 9/10 eyes (90%) ocular 
MMP 
23 IVIG 
Letko E 2004141 
Sami N 2004142 
89% patients (n=18) c ocular 
MMP 
 
This is a very expensive therapy and a scarce resource, but is approved for use in mucous membrane 
pemphigoid in the UK and accessible through local IVIG committees. I use this for patients who have 
failed other therapies. Supplementary Appendix 5 is a protocol for use in ocular MMP with 
acknowledgement to Foster CS, who has provided the evidence for its use in ocular MMP  
24 Infliximab, Etanercept  
John H 2007143  
Prey S 2007144 
Sacher C 2002145 
Canizares MJ 2006146 
Heffernan MP147 
100% (n=7)d ocular and 
extraocular MMP 
These TNFα inhibitors have been little used in small case series. They probably deserve further study. 
I have no experience in their use for ocular MMP 
25 Rituximab 
Le Roux-Villet C 
2011148 
Taverna JA 2007149 
Ross AH 2009150 
Schumann T 2009151 
Lourari S 2010152,153 
Rubsam A 2015154 
Maley A 2016155 
80% (51/64)e ocular and 
extraocular MMP although 
in addition to the 13 
reported failures 3 patients 
in one series only had 
partial control154 and 
another 5 did not respond 
after late relapse155.  
 
Rituximab in these studies has been most often given using the rheumatology protocol in which one 
cycle is a 1gram infusion repeated 14 days later. All these patients have failed conventional therapy 
first. Repeat cycles given after 4 months148 or later155 have been effective in most patients not 
responding to one cycle. The effect of the drug in early cases, the relapse rate, safety and efficacy of 
adjunctive immunosuppressives, and long term management protocols have not been established. 
However, this is currently the most widely used rescue therapy for patients having failure to control 
inflammation by conventional therapy. I use this in patients in whom cyclophosphamide has failed or 
is contraindicated  
26 IVIG and Rituximab 
Foster CS 2010156 
 
100% (n=6) ocular MMP Very high doses of Rituximab were used in this study. I have no experience of combined therapy 
however I have recommended IVIG in Rituximab failures if two cycles of Rituximab 4 months apart 
have been ineffective 2 months after a failure to respond to Rituximab; at this stage there should be 
some residual effect from Rituximab     
27 Daclizumab 
Papaliodis GN 2003157 
100% (n=1) ocular MMP One case report only. I have no experience with this
28 Cyclophosphamide 
and prednisolone vs. 
oral prednisolone  
Foster CS 198646 
(n=24) 12/12 responded to 
cyclophosphamide and oral 
prednisolone versus 5/12 to 
oral prednisolone.  
Confirms use of a steroid sparing drug with prednisolone versus prednisolone alone. No progression 
of disease in cyclophosphamide group versus 7/12 progressing in prednisolone group. 
29 Dapsone versus 
cyclophosphamide 
Foster CS 198646 
(n=40) 14/20 responded to 
dapsone versus 20/20 to 
cyclophosphamide 
Confirms the use of cyclophosphamide rather than dapsone for more severe disease.
30 Combination therapy with drugs other than prednisolone and cyclophosphamide
31 Tauber J 1991133  
 
 
Tauber J 1991: 105 patients. 
Combination therapy was 
used in 24% of patients at 
the end of follow up 
including dapsone +/- 
prednisolone +/- a 
myelosuppressive OR a 
myelopsuppressive + 
prednisolone. 
This influential paper was published over 2 decades ago and was the first to describe the effects of 
treatment of ocular MMP with most non-biological immunomodulators used today, in a large cohort 
of patients. The breakdown of outcomes of different therapies and combinations are less clear. 
However, combination therapy was used in 24% of patients and a recommendation is made for this 
in the paper.    
32 Miserocchi E 2002118 61 patients   22% requiring monotherapy, 21% requiring combinations of 3 or more drugs, and 10% 4 drugs
33 Saw VP 200836 
Williams GP  
201139The same 
approach described in 
a different cohort of 54 
patients.  
388 treatment episodes in 115 patients: 198 single agent treatment episodes (51%) with success or partial success in 73%.  93 
treatment episodes with a myelosuppressive (cyclophosphamide, azathioprine, mycophenolate, methotrexate) OR a sulfa (dapsone, 
sulphapyridine) + prednisolone having 87% success or partial success. 47 treatment episodes with a myelosuppressive + a sulfa 
having 75% success or partial success. 31 treatment episodes with a myelosuppressive (cyclophosphamide, azathioprine, 
mycophenolate, methotrexate) + a sulfa (dapsone, sulphapyridine) + prednisolone having an 87% success or partial success rate. The 
paper includes the data on the outcomes of all 115 patients as supplementary data. 
34 Additional notes on combination therapy 
• Saw VP 200836 is the most comprehensive study on treatment methodology for conventional (non-biological immunomodulatory) therapies. The paper 
includes outcomes of single agent therapy, and multiple agent combinations with rates of side effects. Multiple agent therapy resulted in improved 
response rates compared to single therapy, without an identifiable increase in complication rates over those for monotherapy. A “step up and step down” 
approach is described with the choice of initial therapy related to the severity of disease. Additional drugs are added to, as combination therapy, or 
substituted as monotherapy, when necessary to gain disease control or to avoid side effects. Cyclophosphamide is reserved for the more severe cases, less 
toxic drugs for others, and combinations of sulfas and myelosuppressives when disease control on monotherapy is inadequate. Prednisolone, used in short 
courses, was added to any of the other drugs but most widely in combination with cyclophosphamide.  
• Guidelines for cyclophosphamide therapy are given in Row 19. Dapsone or sulphapyridine was either added to myelosuppressives, when reducing therapy 
 aresults for success (fully controlled inflammation) and qualified success (partial control of inflammation) of 388 individual treatment episodes in 115 patients  
bcombined results of three case series  
ccombined results of two case series  
dcombined results of five case series  
ecombined result of 3 case series and 4 case reports 
 
(stepping down) after disease control, or supplemented with myelosuppressives and/or prednisolone, when disease control was inadequate (stepping up). 
This approach allows maintenance of therapy while additional new agents are introduced.  
• This regimen is what is currently used in the Moorfields Eye Hospital Clinics. This approach has been adopted in UK specialist centres4 and is also what has 
been described also been described in the Foster publications summarized above. However, three review articles113,114,158 have not mentioned the use of 
combined therapy, excepting the use of prednisolone as adjunctive therapy, and have not discussed the value of step up and step down therapy, using 
drug combinations, to maintain therapy during treatment changes and to minimize risk, for ocular MMP. The approach used by Thorne JE et al. 2008 using 
cyclophosphamide as monotherapy after a course of adjunctive prednisolone is effective but probably less safe (see Rows 14,19)  
